Publications

Peer-Reviewed Original Research Articles

  • Malik IA, Khan WA, Qazilbash M, Ata E, Butt A, Khan MA. Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial. Am J Clin Oncol 18:170-5, 4/1995.
  • Qazilbash MH, Walsh CE, Russell SM, Noguchi M, Mann MM, Leonard WJ, Liu JM. Retroviral vector for gene therapy of X-linked severe combined immunodeficiency syndrome. J Hematother 4:91-8, 4/1995.
  • Qazilbash MH, Xiao X, Seth P, Cowan KH, Walsh CE. Cancer gene therapy using a novel adeno-associated virus vector expressing human wild-type. Gene Ther 4:675-82, 7/1997.
  • Qazilbash MH, Liu JM, Vlachos A, Fruchtman S, Messner H, Zipursky A, Alter BP, Young NS. A new syndrome of familial aplastic anemia and chronic liver disease. Acta Haematol 97:164-7, 1997.
  • Hoshino T, Jiang YZ, Dunn D, Paul D, Qazilbash M, Cowan K, Wang J, Barrett J, Liu J. Transfection of interleukin-12 cDNAs into tumor cells induces cytotoxic immune responses against native tumor: implications for tumor vaccination. Cancer Gene Ther 5:150-7, 5/1998.
  • Paul D, Qazilbash MH, Song K, Xu H, Sinha BK, Liu J, Cowan KH. Construction of a recombinant adeno-associated virus (rAAV) vector expressing murine interleukin-12 (IL-12). Cancer Gene Ther 7:308-15, 2/2000.
  • Qazilbash MH, Devetten MP, Abraham J, Lynch JP, Beall CL, Auber M, Weisenborn R, Bunner P, Ericson SG. High-dose therapy and autologous stem cell transplantation in relapsed and refractory Hodgkin's disease: outcome based on a prognostic model. Acta Haematol 110:173-8, 2003.
  • Qazilbash MH, Devetten MP, Abraham J, Lynch JP, Beall CL, Weisenborn R, Bunner P, Ericson SG. Utility of a prognostic scoring system for allogeneic stem cell transplantation in patients with chronic myeloid leukemia. Acta Haematol 109:119-23, 2003.
  • Qazilbash MH, Giralt SA, Champlin RE. Nonmyeloablative stem cell transplantation for chronic myeloid leukemia. Hematol Oncol Clin North Am 18:703-13, xi, 6/2004.
  • Devetten MP, Qazilbash MH, Beall CL, Bunner P, Weisenborn R, Lynch JP, Ericson SG. Thiotepa and fractionated TBI conditioning prior to allogeneic stem cell transplantation for advanced hematologic malignancies: a phase II single institution trial. Bone Marrow Transplant 34:577-80, 10/2004.
  • Qazilbash MH, Qu Z, Hosing C, Couriel D, Donato M, Giralt S, Champlin R. Rituximab-induced acute liver failure after an allogeneic transplantation for chronic myeloid leukemia. Am J Hematol 80:43-5, 9/2005.
  • Qazilbash MH, Saliba R, De Lima M, Hosing C, Couriel D, Aleman A, Roden L, Champlin R, Giralt SA. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer 106:1084-9, 3/2006.
  • Couriel DR, Hosing C, Saliba R, Shpall EJ, Anderlini P, Rhodes B, Smith V, Khouri I, Giralt S, de Lima M, Hsu Y, Ghosh S, Neumann J, Andersson B, Qazilbash M, Hymes S, Kim S, Champlin R, Donato M. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood 107:3074-80, 4/2006.
  • Hosing C, Qazilbash MH, Kebriaei P, Giralt S, Davis MS, Popat U, Anderlini P, Shpall EJ, McMannis J, Korbling M, Champlin RE. Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma. Br J Haematol 133:533-7, 6/2006.
  • Qazilbash MH, Saliba RM, Aleman A, Lei X, Weber D, Carrasco A, Champlin RE, Giralt SA. Risk factors for relapse after complete remission with high-dose therapy for multiple myeloma. Leuk Lymphoma 47:1360-4, 7/2006.
  • Kebriaei P, Saliba RM, Ma C, Ippoliti C, Couriel DR, de Lima M, Giralt S, Qazilbash MH, Gajewski JL, Ha CS, Champlin RE, Khouri IF. Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia. Bone Marrow Transplant 38:203-9, 8/2006.
  • Saliba RM, de Lima M, Giralt S, Andersson B, Khouri IF, Hosing C, Ghosh S, Neumann J, Hsu Y, De Jesus J, Qazilbash MH, Champlin RE, Couriel DR. Hyper-acute GVHD: risk factors, outcomes, and clinical implications. Blood 109(7):2751-8, 11/2006.
  • Qazilbash MH, Ueno N , Hosing C , de Lima M , Cortes J , Massaro A , Rivera Z, Deavers M , Adachi JA, Champlin RE. Strongyloidiasis after Unrelated Non-myeloablative Allogeneic Stem Cell Transplantation. Bone Marrow Transplant 38(5):393-4, 2006.
  • Qazilbash MH, Saliba, R., Hosing, C., de Lima, M., Couriel, D., Mendoza, F., Qureshi, S. R., Weber, D. M., Wang, M., Flosser, T., Kebriaei, P., Popat, U., Alousi, A. M., Champlin, R., Giralt, S. Autologous Stem Cell Transplantation is Safe and Feasible in Elderly Patients with Multiple Myeloma. Bone Marrow Transplant 39(5):279-83, 3/2007. e-Pub 1/2007.
  • Qazilbash MH, Saliba RM, Ahmed B, Parikh G, Mendoza F, Ashraf N, Hosing C, Flosser T, Weber DM, Wang M, Couriel DR, Popat U, Kebriaei P, Alousi AM, Anderlini P, Naeem RC, Champlin RE, Giralt SA. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. Biol Blood Marrow Transplant. 13(9):1066-72, 9/2007. e-Pub 7/2007.
  • Oran B, Giralt S, Couriel D, Hosing C, Shpall EJ, de Meis E, Khouri IF, Qazilbash M, Anderlini P, Kebriaei P, Popat U, Carrasco-Yalan A, Champlin RE, de Lima M. Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation. Leukemia. 5, 7/2007.
  • Christoforidou AV, Saliba RM, Williams P, Qazilbash M, Roden L, Aleman A, Weber D, Mendoza F, Podoloff D, Wendt R 3rd, Breitz H, Alexanian R, Champlin R, Giralt S. Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes. Biol Blood Marrow Transplant. 13(5):543-9, 5/2007. e-Pub 2/2007.
  • de Lima M, Champlin RE, Thall PF, Wang X, Martin TG 3rd, Cook JD, McCormick G, Qazilbash M, Kebriaei P, Couriel D, Shpall EJ, Khouri I, Anderlini P, Hosing C, Chan KW, Andersson BS, Patah PA, Caldera Z, Jabbour E, Giralt S. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia. 22(2):258-64, 2/2008. e-Pub 11/2007.
  • Anderlini P, Saliba R, Acholonu S, Giralt SA, Andersson B, Ueno NT, Hosing C, Khouri IF, Couriel D, de Lima M, Qazilbash MH, Pro B, Romaguera J, Fayad L, Hagemeister F, Younes A, Munsell, MF, Champlin RE. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin’s lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica 93:257-264, 1/2008. e-Pub 1/2008.
  • Jones JA, Qazilbash MH, Shih YC, Cantor SB, Cooksley CD, Elting LS. In-hospital complications of autologous hematopoietic stem cell transplantation for lymphoid malignancies : clinical and economic outcomes from the nationwide inpatient sample. Cancer 112(5):1096-105, 3/2008. e-Pub 1/2008.
  • Hosing C, Saliba RM, Okoroji GJ, Popat U, Couriel D, Ali T, De Padua Silva L, Kebriaei P, Alousi A, De Lima M, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri I. High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age. Annals of Oncology 19(6):1166-1171, 5/2008.
  • Alousi AM, Saliba RM, Okoroji GJ, Macapinlac HA, Hosing C, Korbling M, Samuels BI, Popat U, Kebriaei P, Anderlini P, Qazilbash MH, de Lima M, Giralt SA, Champlin RE, Khouri IF. Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation. Br J Haematol 142(5):786-92, 6/2008.
  • Qazilbash MH, Saliba RM, Nieto Y, Parikh G, Pelosini M, Khan FB, Jones RB, Hosing C, Mendoza F, Weber DM, Wang M, Popat U, Alousi A, Anderlini P, Champlin RE, Giralt S. Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan: Results of a Phase II Randomized Trial. Biol Blood Marrow Transplant 14(12):1401-7, 12/2008.
  • Hosing C, Saliba RM, Ahlawat S, Körbling M, Kebriaei P, Alousi A, De Lima M, Okoroji JG, McMannis J, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri I, Popat U. Poor hematopoietic stem cell mobilizers: A single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol 84(6):335-7, 6/2009.
  • Kurian S, Qazilbash M, Fay J, Wolff S, Herzig R, Hobbs G, Bunner P, Weisenborn R, Aya-Ay M, Lynch J, Ericson S. Complete response after high-dose chemotherapy and autologous hemopoietic stem cell transplatation in metastatic breast cancer results in survival benefit. Breast Journal 12(6):531-5, 12/2006.
  • Ozdemir E, Saliba RM, Champlin RE, Couriel DR, Giralt SA, de Lima M, Khouri IF, Hosing C, Kornblau SM, Anderlini P, Shpall EJ, Qazilbash MH, Molldrem JJ, Chemaly RF, Komanduri KV. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant 40(2):125-36, 7/2007.
  • Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P, Shpall E, McMannis J, Körbling M, Alousi A, Andersson B, Nieto Y, Kebriaei P, Khouri I, de Lima M, Weber D, Thomas S, Wang M, Jones R, Champlin R, Giralt S. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 15(6):718-23, 6/2009. e-Pub 4/2009.
  • Parikh GC, Amjad AI, Saliba RM, Kazmi SM, Khan ZU, Lahoti A, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Popat U, Alousi AM, Champlin RE, Giralt SA, Qazilbash MH. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant 15(7):812-6, 7/2009.
  • Wang M, Delasalle K, Feng L, Thomas S, Giralt S, Qazilbash M, Handy B, Lee JJ, Alexanian R. CR represents an early index of potential long survival in multiple myeloma. Bone Marrow Transplant 45(3):498-504, 3/2010.
  • Parmar S, de Lima M, Zou Y, Patah P, Liu P, Cano P, Rondon G, Pesoa S, de Padua Silva L, Qazilbash MH, Hosing C, Popat U, Kebriaei P, Shpall EJ, Giralt S, Champlin RE, Stastny P, Fernandez-Vina M. Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease. Blood 114(14):2884-7, 10/2009. e-Pub 8/2009.
  • Ciurea SO, Saliba R, Rondon G, Pesoa S, Cano P, Fernandez-Vina M, Qureshi S, Worth LL, McMannis J, Kebriaei P, Jones RB, Korbling M, Qazilbash M, Shpall EJ, Giralt S, de Lima M, Champlin RE, Gajewski J. Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. Bone Marrow Transplant 45(3):429-36, 3/2010.
  • de Souza JA, Saliba RM, Patah P, Rondon G, Ribeiro R, de Padua Silva L, Qazilbash MH, Hosing C, Popat U, Efebera Y, Champlin RE, de Lima M. Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 15(9):1094-9, 9/2009.
  • Qazilbash MH, Amjad AI, Qureshi S, Qureshi SR, Saliba RM, Khan ZU, Hosing C, Giralt SA, de Lima MJ, Popat UR, Yusuf SW, Champlin RE. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Low Left Ventricular Ejection Fraction. Biol Blood Marrow Transplant 15(10):1265-70, 10/2009. e-Pub 8/2009.
  • Efebera YA, Qureshi SR, Cole SM, Saliba R, Pelosini M, Patel RM, Koca E, Mendoza FL, Wang M, Shah J, Alousi A, Hosing C, Popat U, Kebriaei P, Anderlini P, Khouri IF, Champlin R, Giralt S, Qazilbash MH. Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma. Biol Blood Marrow Transplant 16(8):1122-1129, 8/2010. e-Pub 2/2010.
  • Kazmi SM, Saliba RM, Donato M, Wang M, Hosing C, Qureshi S, Anderlini P, Popat U, Champlin RE, Giralt SA, Qazilbash MH. Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma. Bone Marrow Transplant 46(4):510-5, 4/2011. e-Pub 6/2010.
  • Sharma M, Qureshi SR, Champlin RE, Popat U, Giralt S, Qazilbash MH. The outcome of IgD myeloma after autologous hematopoietic stem cell transplantation is similar to other Ig subtypes. Am J Hematol 85(7):502-4, 7/2010.
  • Kebriaei P, Madden T, Kazerooni R, Wang X, Thall PF, Ledesma C, Nieto Y, Shpall EJ, Hosing C, Qazilbash M, Popat U, Khouri I, Champlin RE, Jones RB, Andersson BS. Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with Advanced Lymphoid Malignancies. Biol Blood Marrow Transplant 17(3):412-20, 3/2011. e-Pub 7/2010.
  • Bashir Q, De Lima MJ, McMannis JD, Garcia-Manero G, Shpall E, Kantarjian H, Cortes JE, O'Brien SM, Jones D, Qazilbash M, Wei W, Giralt SA, Champlin RE, Hosing C. Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy. Leuk Lymphoma 51(8):1478-84, 8/2010.
  • Ma Q, Wang C, Jones D, Quintanilla KE, Li D, Wang Y, Wieder ED, Clise-Dwyer K, Alatrash G, Mj Y, Munsell MF, Lu S, Qazilbash MH, Molldrem JJ. Adoptive transfer of PR1 cytotoxic T lymphocytes associated with reduced leukemia burden in a mouse acute myeloid leukemia xenograft model. Cytotherapy 12(8):1056-62, 12/2010. e-Pub 8/2010.
  • Anderlini P, Acholonu SA, Okoroji GJ, Bassett RE, Shpall EJ, Qazilbash MH, Popat UR, Worth LL, Giralt SA, Champlin RE. Fludarabine, cyclophosphamide, and antithymocyte globulin for matched related and unrelated allogeneic stem cell transplant in severe aplastic anemia. Leuk Lymphoma 52(1):137-41, 1/2011.
  • Bashir Q, Langford LA, Parmar S, Champlin RE, Qazilbash MH. Primary Systemic Amyloid Light Chain Amyloidosis Decompensating After Filgrastim-Induced Mobilization and Stem-Cell Collection. J Clin Oncol 29(4):e79-80, 2/2011. e-Pub 11/2010.
  • Alatrash G, de Lima M, Hamerschlak N, Pelosini M, Wang X, Xiao L, Kerbauy F, Chiattone A, Rondon G, Qazilbash MH, Giralt SA, de Padua Silva L, Hosing C, Kebriaei P, Zhang W, Nieto Y, Saliba RM, Champlin RE, Andersson BS. Myeloablative Reduced-Toxicity i.v. Busulfan-Fludarabine and Allogeneic Hematopoietic Stem Cell Transplant for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome in the Sixth Through Eighth Decades of Life. Biol Blood Marrow Transplant. e-Pub 2/2011.
  • Popat U, de Lima MJ, Saliba RM, Anderlini P, Andersson BS, Alousi AM, Hosing C, Nieto Y, Parmar S, Khouri IF, Kebriaei P, Qazilbash M, Champlin RE, Giralt SA. Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR. Bone Marrow Transplant. e-Pub 3/2011.
  • Hosing C, Smith V, Rhodes B, Walters K, Thompson R, Qazilbash M, Khouri I, de Lima M, Balzer RJ, McMannis J, Champlin R, Giralt S, Popat U. Assessing the charges associated with hematopoietic stem cell mobilization and remobilization in patients with lymphoma and multiple myeloma undergoing autologous hematopoietic peripheral blood stem cell transplantation. Transfusion. e-Pub 5/2011.
  • Bashir Q, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Orlowski RZ, Thomas SK, Shah J, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Feasibility of autologous hematopoietic stem cell transplantation in patients aged =70 years with multiple myeloma. Leuk Lymphoma. e-Pub 7/2011.
  • Sharma M, Ravandi F, Bayraktar UD, Chiattone A, Bashir Q, Giralt S, Chen J, Qazilbash M, Kebriaei P, Konopleva M, Andreeff M, Cortes J, McCue D, Kantarjian H, Champlin RE, de Lima M. Treatment of FLT3-ITD Positive Acute Myeloid Leukemia Relapsing After Allogeneic Stem Cell Transplantation with Sorafenib. Biol Blood Marrow Transplant. e-Pub 7/2011.
  • Sharma M, Khan H, Thall PF, Orlowski RZ, Bassett RL, Shah N, Bashir Q, Parmar S, Wang M, Shah JJ, Hosing CM, Popat UR, Giralt SA, Champlin RE, Qazilbash MH. A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer 118(9):2507-2515, 5/2012. e-Pub 9/2011.
  • Joseph RW, Alousi A, Konda B, Komanduri K, Neumann J, Trevino C, Stolar K, Qazilbash M, Hosing C, Kebriaei P, Couriel DR, Champlin RE, Saliba R, Popat U. High incidence of vitamin D deficiency in patients undergoing allogeneic stem cell transplantation. Am J Hematol. e-Pub 7/2011.
  • Krishnan A, Pasquini MC, Logan B, Stadtmauer EA, Vesole DH, Alyea E, Antin JH, Comenzo R, Goodman S, Hari P, Laport G, Qazilbash MH, Rowley S, Sahebi F, Somlo G, Vogl DT, Weisdorf D, Ewell M, Wu J, Geller NL, Horowitz MM, Giralt S, Maloney DG, on behalf of the Blood Marrow Transplant Clinical Trials Network (BMT CTN). Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol 12(13):1195-1203, 12/2011. e-Pub 9/2011.
  • Ciurea SO, Saliba RM, Hamerschlak N, Karduss Aurueta AJ, Bassett R, Fernandez-Vina M, Petropoulos D, Worth LL, Chan KW, Couriel DR, Rondon G, Sharma M, Qazilbash M, Jones RB, Kebriaei P, McMannis J, Hosing CM, Nieto Y, Champlin RE, Shpall EJ, de Lima M. Fludarabine, Melphalan, Thiotepa and ATG Conditioning for Unrelated Cord Blood Transplantation. Leuk Lymphoma 53(5):901-906, 5/2012. e-Pub 10/2011.
  • Bashir Q, Munsell MF, Giralt S, de Padua Silva L, Sharma M, Couriel D, Chiattone A, Popat U, Qazilbash MH, Fernandez-Vina M, Champlin RE, de Lima MJ. Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplantation. Leuk Lymphoma 53(5):915-919, 5/2012. e-Pub 10/2011.
  • Howell JE, Gulbis AM, Champlin RE, Qazilbash MH. Retrospective analysis of weekly intravenous immunoglobulin prophylaxis versus intravenous immunoglobulin by IgG level monitoring in hematopoietic stem cell transplant recipients. Am J Hematol 87(2):172-174, 2/2012. e-Pub 10/2011.
  • Shah N, Ahmed F, Bashir Q, Qureshi S, Dinh Y, Rondon G, Wen S, Thall P, Khan H, Giralt S, Champlin R, Qazilbash MH. Durable remission with salvage second autotransplants in patients with multiple myeloma. Cancer 118(14):3549-3555, 7/2012. e-Pub 11/2011.
  • Klimov VI, Stewart JT, Padilha LA, Qazilbash M, Pietryga JM, Midgett AG, Luther J, Beard MC, Nozik A. Comparison of carrier multiplication yields in PbS and PbSe nanocrystals: The role of competing energy-loss processes. Nano Lett 12(2):622-628, 2/2012. e-Pub 12/2011.
  • Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Ledesma C, Andersson BS, Jones R, Popat UR, Hosing CM, Nieto Y, Qazilbash MH, Ueno NT, Giralt SA, de Lima MJ, Champlin RE. Donor leukocyte infusions (DLIs) in recurrent hodgkin lymphoma (HL) following allogeneic stem cell transplantation: ten-year experience at the M.D. anderson cancer center. Leuk Lymphoma 53(6):1239-1241, 6/2012. e-Pub 12/2011.
  • Westin JR, Saliba RM, De Lima M, Alousi A, Hosing C, Qazilbash MH, Khouri IF, Shpall EJ, Anderlini P, Rondon G, Andersson BS, Champlin R, Couriel DR. Steroid-Refractory Acute GVHD: Predictors and Outcomes. Adv Hematol 2011:601953, 2011. e-Pub 11/2011. PMCID: PMC3216266.
  • Bashir Q, Khan H, Orlowski RZ, Amjad AI, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Thomas SK, Shah JJ, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol 87(2):272-276, 2/2012. e-Pub 12/2011.
  • Beitinjaneh AM, Saliba R, Bashir Q, Shah N, Parmar S, Hosing C, Popat U, Anderlini P, Dinh Y, Qureshi S, Rondon G, Champlin RE, Giralt SA, Qazilbash MH. Durable Responses after Donor Lymphocyte Infusion for Patients with Residual Multiple Myeloma following Non-myeloablative Allogeneic Stem Cell Transplantation. Leuk Lymphoma 53(8):1525-1529, 8/2012. e-Pub 1/2012.
  • Nieto Y, Thall P, Valdez B, Andersson B, Popat U, Anderlini P, Shpall EJ, Bassett R, Alousi A, Hosing C, Kebriaei P, Qazilbash M, Gulbis A, Chancoco C, Bashir Q, Ciurea S, Khouri I, Parmar S, Shah N, Worth L, Rondon G, Champlin R, Jones RB. High-Dose Infusional Gemcitabine Combined with Busulfan and Melphalan with Autologous Stem-Cell Transplant in Patients with Refractory Lymphoid Malignancies. Biol Blood Marrow Transplant 18(11):1677-1686, 11/2012. e-Pub 5/2012.
  • McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Seiler M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Anderson KC, Linker C. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 366(19):1770-81, 5/2012.
  • Kebriaei P, Madden T, Wang X, Thall PF, Ledesma C, de Lima M, Shpall EJ, Hosing C, Qazilbash M, Popat U, Alousi A, Nieto Y, Champlin RE, Jones RB, Andersson BS. Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL. Bone Marrow Transplant 48(1):26-31, 1/2013. e-Pub 6/2012.
  • Ciurea SO, Mulanovich V, Saliba RM, Bayraktar UD, Jiang Y, Bassett R, Wang SA, Konopleva M, Fernandez-Vina M, Montes N, Bosque D, Chen J, Rondon G, Alatrash G, Alousi A, Bashir Q, Korbling M, Qazilbash M, Parmar S, Shpall E, Nieto Y, Hosing C, Kebriaei P, Khouri I, Popat U, de Lima M, Champlin RE. Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplant. Biol Blood Marrow Transplant 18(12):1835-1844, 12/2012. e-Pub 7/2012.
  • Foglietta M, Neelapu SS, Kwak LW, Jiang Y, Nattamai D, Lee ST, Fowler DH, Sportes C, Gress RE, Steinberg SM, Vence LM, Radvanyi L, Dwyer KC, Qazilbash MH, Bryant RN, Bishop MR. Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients. Bone Marrow Transplant 48(2):269-277, 2/2013. e-Pub 7/2012.
  • Kebriaei P, Basset R, Ledesma C, Ciurea S, Parmar S, Shpall EJ, Hosing C, Khouri I, Qazilbash M, Popat U, Alousi A, Nieto Y, Jones RB, de Lima M, Champlin RE, Andersson BS. Clofarabine Combined with Busulfan Provides Excellent Disease Control in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 18(12):1819-1826, 12/2012. e-Pub 6/2012.
  • Bayraktar UD, Bashir Q, Qazilbash M, Champlin RE, Ciurea SO. Fifty Years of Melphalan Use in Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 19(3):344-356, 3/2013. e-Pub 8/2012.
  • Hosing C, Munsell MF, Reuben JM, Popat U, Lee BN, Gao H, Körbling M, Shpall EJ, Kebriaei P, Alousi A, De Lima M, McMannis J, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri I. A randomized study comparing chemotherapy followed by G-CSF alone or in combination with GM-CSF for mobilization of peripheral blood stem cells in patients with non-Hodgkin's lymphomas. J Blood Med 1:49-55, 2010. e-Pub 4/2010. PMCID: PMC3262333.
  • Oran B, Popat U, Rondon G, Ravandi F, Garcia-Manero G, Abruzzo L, Andersson BS, Bashir Q, Chen J, Kebriaei P, Khouri IF, Koca E, Qazilbash MH, Champlin R, de Lima M. Significance of Persistent Cytogenetic Abnormalities at Myeloablative Allogeneic Stem Cell Transplantation in First Complete Remission. Biol Blood Marrow Transplant 19(2):214-220, 2/2013. e-Pub 9/2012.
  • Poon LM, Bassett Jr R, Rondon G, Hamdi A, Qazilbash M, Hosing C, Jones RB, Shpall EJ, Popat UR, Nieto Y, Worth LL, Cooper L, De Lima M, Champlin RE, Kebriaei P. Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia. Bone Marrow Transplant 48(5):666-670, 3/2013. e-Pub 10/2012.
  • Nieto Y, Popat U, Anderlini P, Valdez B, Andersson B, Liu P, Hosing C, Shpall EJ, Alousi A, Kebriaei P, Qazilbash M, Parmar S, Bashir Q, Shah N, Khouri I, Rondon G, Champlin R, Jones RB. Autologous Stem-Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome. Biol Blood Marrow Transplant 19(3):410-417, 3/2013. e-Pub 11/2012.
  • de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M, Alousi A, Saliba R, McMannis JD, Kaur I, Kebriaei P, Parmar S, Popat U, Hosing C, Champlin R, Bollard C, Molldrem JJ, Jones RB, Nieto Y, Andersson BS, Shah N, Oran B, Cooper LJ, Worth L, Qazilbash MH, Korbling M, Rondon G, Ciurea S, Bosque D, Maewal I, Simmons PJ, Shpall EJ. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med 367(24):2305-15, 12/2012.
  • Aung FM, Lichtiger B, Bassett R, Liu P, Alousi A, Bashier Q, Ciurea SO, de Lima MJ, Hosing C, Kebriaei P, Nieto Y, Oran B, Parmar S, Qazilbash M, Shah N, Khouri I, Champlin RE, Popat U. Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation. Br J Haematol. e-Pub 1/2013.
  • Yilmaz M, Chemaly RF, Han XY, Thall PF, Fox PS, Tarrand JJ, De Lima MJ, Hosing CM, Popat UR, Shpall E, Champlin RE, Qazilbash MH. Adenoviral infections in adult allogeneic hematopoietic SCT recipients: a single center experience. Bone Marrow Transplant. e-Pub 3/2013.
  • Karuturi M, Hosing C, Fanale M, Medeiros LJ, Alousi AM, de Lima MJ, Qazilbash MH, Kebriaei P, Younes A, Khouri I, Andersson BS, Champlin R, Anderlini P, Popat U. High-dose chemotherapy and Autologous Stem Cell Transplantation For Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). Biol Blood Marrow Transplant. e-Pub 3/2013.
  • Lu G, Muddasani R, Orlowski RZ, Abruzzo LV, Qazilbash MH, You MJ, Wang Y, Zhao M, Chen S, Glitza IC, Medeiros LJ. Plasma cell enrichment enhances detection of high-risk cytogenomic abnormalities by fluorescence in situ hybridization and improves risk stratification of patients with plasma cell neoplasms. Arch Pathol Lab Med 137(5):625-31, 5/2013.
  • Poon LM, Hamdi A, Saliba R, Rondon G, Ledesma C, Kendrick M, Qazilbash M, Hosing C, Jones RB, Popat UR, Nieto Y, Alousi A, Ciurea S, Shpall EJ, Champlin RE, Kebriaei P. Outcomes of adults with acute lymphoblastic leukemia (ALL) following relapse post allogeneic hematopoietic stem cell transplantation (HSCT). Biol Blood Marrow Transplant. e-Pub 4/2013.
  • Valdez BC, Wang G, Murray D, Nieto Y, Li Y, Shah J, Turturro F, Wang M, Weber DM, Champlin RE, Qazilbash MH, Andersson BS. Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma; relevance of p53 and its clinical implications. Exp Hematol. e-Pub 5/2013.
  • Sasaki K, Lu G, Saliba RM, Bashir Q, Hosing C, Popat U, Shah N, Parmar S, Dinh Y, Ahmed S, Shpall EJ, Kebriaei P, Shah JJ, Orlowski RZ, Champlin R, Qazilbash MH. Impact Of  t(11;14)(q13;q32) On The Outcome Of Autologous Hematopoietic Cell Transplantation In Multiple Myeloma. Biol Blood Marrow Transplant. e-Pub 5/2013.
  • Smith VR, Popat U, Ciurea S, Nieto Y, Anderlini P, Rondon G, Alousi A, Qazilbash M, Kebriaei P, Khouri I, de Lima M, Champlin R, Hosing C. Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization. Am J Hematol. e-Pub 6/2013.
  • Pemmaraju N, Tanaka MF, Ravandi F, Lin H, Baladandayuthapani V, Rondon G, Giralt SA, Chen J, Pierce S, Cortes J, Kantarjian H, Champlin RE, De Lima M, Qazilbash MH. Outcomes in Patients With Relapsed or Refractory Acute Promyelocytic Leukemia Treated With or Without Autologous or Allogeneic Hematopoietic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk. e-Pub 6/2013.
  • Bashir Q, Khan H, Thall PF, Liu P, Shah N, Kebriaei P, Parmar S, Oran B, Ciurea S, Nieto Y, Jones R, Hosing CM, Popat UR, Dinh YT, Rondon G, Orlowski RZ, Shah JJ, De Lima M, Shpall E, Champlin R, Giralt S, Qazilbash M. A Randomized Phase II Trial of Fludarabine/Melphalan 100 versus Fludarabine/Melphalan 140 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma. Biol Blood Marrow Transplant. e-Pub 7/2013.
  • Thall PF, Nguyen HQ, Braun TM, Qazilbash MH. Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes. Biometrics:1-10. e-Pub 8/2013.
  • Hosing C, Saliba RM, Hamerschlak N, Kutner JM, Sakashita AM, Kondo AT, Rodrigues M, Fernande JF, Chiattone A, Chiattone VC, Barros JC, Chiattone CS, Chiattone R, Popat U, Qazilbash M, Tang XW, Wu D, Majilis A, de Lima M, Anguita T. Peripheral blood stem cell yield calculated using preapheresis absolute CD34+ cell count, peripheral blood volume processed, and donor body weight accurately predicts actual yield at multiple centers. Transfusion. e-Pub 10/2013.
  • Mehta RS, Di Stasi A, Andersson BS, Nieto Y, Jones R, de Lima M, Hosing C, Popat U, Kebriaei P, Oran B, Alousi A, Rezvani K, Qazilbash M, Bashir Q, Bollard C, Cooper L, Worth L, Tewari P, McNiece I, Willhelm K, Champlin R, Shpall EJ. The Development of a Myeloablative, Reduced-Toxicity, Conditioning Regimen for Cord Blood Transplantation. Clin Lymphoma Myeloma Leuk. e-Pub 10/2013.
  • Alexanian R, Wang M, Delasalle K, Wang S, Qazilbash M, Handy B, Weber D. Value of novel agents and intensive therapy for patients with multiple myeloma. Bone Marrow Transplant. e-Pub 12/2013.
  • Yusuf SW, Solhpour A, Banchs J, Lopez-Mattei JC, Durand JB, Iliescu C, Hassan SA, Qazilbash MH. Cardiac amyloidosis. Expert Rev Cardiovasc Ther. e-Pub 1/2014.
  • Patel K, Nusrat M, Shah N, Bashir Q, Parmar S, Shah J, Thomas S, Weber D, Orlowski RZ, Champlin R, Qazilbash MH. Durable responses with autologous hematopoietic SCT in patients with POEMS syndrome. Bone Marrow Transplant. e-Pub 1/2014.
  • Wang XS, Shi Q, Shah N, Heijnen CJ, Cohen EN, Reuben JM, Orlowski RZ, Qazilbash MH, Johnson VE, Williams LA, Mendoza TR, Cleeland CS. Inflammatory Markers and Development of Symptom Burden in Patients with Multiple Myeloma during Autologous Stem Cell Transplantation. Clin Cancer Res. e-Pub 1/2014.
  • Zhou Y, Slack R, Jorgensen JL, Wang SA, Rondon G, de Lima M, Shpall E, Popat U, Ciurea S, Alousi A, Qazilbash M, Hosing C, O'Brien S, Thomas D, Kantarjian H, Medeiros LJ, Champlin RE, Kebriaei P. The Effect of Peritransplant Minimal Residual Disease in Adults With Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk. e-Pub 1/2014.
  • Alsina M, Becker PS, Zhong X, Adams A, Hari P, Rowley S, Stadtmauer EA, Vesole DH, Logan B, Weisdorf D, Qazilbash M, Popplewell LL, McClune B, Bensinger W, Riches M, Giralt SA, Pasquini MC, Resource for Clinical Investigation in Blood and Marrow Transplantation. Lenalidomide Maintenance for High-Risk Multiple Myeloma after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. e-Pub 4/2014.
  • Glitza IC, Lu G, Shah R, Bashir Q, Shah N, Champlin RE, Shah J, Orlowski RZ, Qazilbash MH. Chromosome 8q24.1/c-MYC Abnormality: A Marker for High-Risk Myeloma. Leuk Lymphoma:1-18. e-Pub 5/2014.
  • Gul Z, Bashir Q, Cremer M, Yusuf SW, Gunaydin H, Arora S, Slone S, Nieto Y, Parmar S, Shah N, Dinh YT, Hosing CM, Popat UR, Kebriaei P, Champlin RE, Qazilbash MH. Short-term Cardiac Toxicity of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Leuk Lymphoma:1-8. e-Pub 5/2014.
  • Parmar S, Kongtim P, Champlin R, Dinh Y, Elgharably Y, Wang M, Bashir Q, Shah JJ, Shah N, Popat U, Giralt SA, Orlowski RZ, Qazilbash MH. Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up. Bone Marrow Transplant. e-Pub 6/2014.
  • Tang G, Wang SA, Lu V, Lee HC, Qazilbash MH, Wang XI, Yin CC, Orlowski R, Wang Y, Patel A, Medeiros LJ, Lu G. Clinically silent clonal cytogenetic abnormalities arising in patients treated for lymphoid neoplasms. Leuk Res. e-Pub 6/2014.
  • Wu W, Merriman K, Nabaah A, Seval N, Seval D, Lin H, Wang M, Qazilbash MH, Baladandayuthapani V, Berry D, Orlowski RZ, Lee MH, Yeung SC. The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma. Br J Cancer. e-Pub 6/2014.
  • Hamdi A, Afrough A, Muzzafar T, Popat UR, Hosing CM, Qazilbash MH, Lu G. Donor Cell-Derived Myelodysplastic Syndrome With Ring Chromosome 7 After Allogeneic Hematopoietic Stem Cell Transplant in 2 Patients With Lymphomas as Primary Disease. Clin Lymphoma Myeloma Leuk. e-Pub 6/2014.
  • Pemmaraju N, Shah D, Kantarjian H, Orlowski RZ, Nogueras González GM, Baladandayuthapani V, Jain N, Wagner V, Garcia-Manero G, Shah J, Ravandi F, Pierce S, Takahashi K, Daver N, Nazha A, Verstovsek S, Jabbour E, De Lima M, Champlin R, Cortes J, Qazilbash MH. Characteristics and Outcomes of Patients With Multiple Myeloma Who Develop Therapy-Related Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. e-Pub 7/2014.
  • Invited Articles
  • Qazilbash, M, Young, N, Liu, J. Vectors and target cells for gene therapy of blood diseases. Trends in Cardiovascular Medicine 6:25-30, 1996.
  • Qazilbash, M, Liu, J. Recent developments in gene therapy for severe combined immunodeficiency and Fanconi anemia. Molecular Therapeutics 1:151-155, 1998.
  • Qazilbash MH, Giralt S, Champlin R. Non-Myeloablative Transplantation for Chronic Myeloid Leukemia. Hematology-Oncology Clinics of North America, 2004.

    • Abstracts
  • Qazilbash MH, Liu JM, Vlachos A, et al. Familial aplastic anemia associated with liver disease. Blood Suppl. 84:8A, 1994.
  • Qazilbash MH, Walsh CE, Young NS, Liu JM. Progress towards gene therapy of X-linked SCID. Clinical Research. 42:202A, 1994.
  • Qazilbash MH, Xiao X, Seth P, Cowan KH, Walsh CE. Cancer gene therapy with a novel adeno-associated virus vector expressing p53. Gene Therapy Meeting, Cold Spring Harbor Laboratory, New York:245, 1996.
  • Qazilbash, MH, Xiao, X, Paul, D, et al. Anti-tumor activity of a recombinant adeno-associated virus vector expressing wild-type p53 in vivo. Journal of Investigative Medicine 45:266A, 1997.
  • Paul, D, Qazilbash, MH, Seth, P, Liu, J, Cowan, KH. Construction of a recombinant adeno-associated virus (rAAV) vector for interleukin-12 (IL-12) mediated cancer gene therapy. Cancer Research 39:3520, 1998.
  • Qazilbash, M, Saliba, R, Aleman, A, Roden, L, de Lima, M, Couriel, D, Hosing, C, Kebriaei, P, Champlin, R, Giralt, S. Arsenic trioxide with ascorbic acid and high-dose melphalan: a new preparative regimen for autologous hematopoietic stem cell transplantation for multiple myeloma. 2000.
  • Qazilbash, M, Lynch, J, Beall C, Weisenborn, R, Bumer, P, Hobbs, G, Auber, M, Ericson, S. Efficacy of a BCNU-based high-dose conditioning regimen(CBVi) followed by autologous hematopoietic stem cell transplantation (HSCT) in relapsed or refractory Hodgkin’s disease (HD). Blood 96(11):374b, 2000.
  • Kurian, S, Qazilbash, M, Lynch, J, Beall, C, Weisenborn, R, Bummer, P, Hobbs, G, Auber, M, Ericson, S. High-dose Ara-C/Idarubicin induction and high-dose etoposide/cytoxan intensification in AML. Blood 96(11):213b, 2000.
  • Qazilbash, M, Lynch, J, Beall C, Weisenborn, R, Bumer, P, Hobbs, G, Auber, M, Ericson, S. High-dose therapy (HDT) with autologous hematopoietic stem cell transplantation (HSCT) in multiple myeloma: experience of a single academic BMT center. Blood 96(11):374b, 2000.
  • Qazilbash, M, Lynch, J, Beall, C, et al. High-dose therapy with autologous stem cell transplantation in multiple myeloma: experience of a single academic BMT Center. Tenth International Symposium on Autologous Blood and Marrow Transplantation, 2000.
  • Qazilbash, M, Lynch, J, Beall C, Weisenborn, R, Bumer, P, Hobbs, G, Auber, M, Ericson, S. Outcome of unrelated donor stem cell transplantation for hematologic malignancies: preliminary data from a single academic transplant center. Blood 96(11):364b, 2000.
  • Qazilbash, M, Lynch, J, Beall, C, Weisenborn, R, Bumer, P, Hobbs, G, Auber, M, Ericson, S. Safety and efficacy of high-dose busulfan and cyclophosphamide for chronic myelogenous leukemia: effect cytoxan dose on outcome. Blood 96(11):357b, 2000.
  • Ericson, S, Henderson, A, Watkins, K, Buckhalter, G, Weisenborn, R, Bunner, P, Beall, C, Devetten, M, Qazilbash, M, Lynch, J. Administration of G-CSF based on WBC count rather than a fixed day after autologous PBSCT results in decreased utilization of G-CSF without compromising neutrophil engraftment. ISHAGE, 2001.
  • Qazilbash, M, Devetten, M, Lynch, J, Beall C, Auber, M, Weisenborn, R, Bumer, P, Ericson, S. High-dose therapy and autologous stem cell transplantation in relapsed and refractory hodgkin’s disease: outcome based on a prognostic model. Pan-Pacific Lymphoma Conference, 2001.
  • Qazilbash, M, Devetten, M, Lynch, J, Beall C, Auber, M, Weisenborn, R, Bumer, P, Ericson, S. High-dose therapy with autologous transplantation for low-grade non-Hodgkin’s lymphoma. Pan-Pacific Lymphoma Conference, 2001.
  • Qazilbash, M, Lynch, J, Beall C, Auber, M, Weisenborn, R, Bumer, P, Ericson, S. The impact of histology on high-dose therapy and autologous stem cell transplantation in patients with relapsed non-hodgkin’s lymphoma. Biol Blood Marrow Transplant 7(2):85, 2001.
  • Qazilbash, M, Lynch, J, Beall C, Auber, M, Weisenborn, R, Bumer, P, Ericson, S. The utility of a prognostic scoring system for allogeneic stem cell transplantation in patients with chronic myelogenous leukemia. Biol Blood Marrow Transplant 7:103, 2001.
  • Qazilbash, M, Saliba, R, Aleman, A, Lei, X, Weber, D, Carrasco, A, Champlin, R, Giralt, S. Risk factors for relapse after CR with high-dose therapy for multiple myeloma. . Blood 102(11):982a, 2003.
  • Khouri, I, Saliba, R, Partow, K, Ma, C, Ippoliti, C, Couriel, D, de Lima, M, Giralt, S, Qazilbash, M, Gajewski, J, Champlin, R. Allogeneic Transplantation for Adult Acute Lymphoblastic Leukemis (ALL) with Rituximab or Campath I-H. Blood 104(11):366b, 2004.
  • de Lima, M, Thall, P, Shahjahan, M, Xuemei, W, Couriel, D, Anderlini, P, Hosing, C, Qazilbash, M, McCormick, G, Ippoliti, C, Donato, M, Martin, T, Metoyer, L, Griffin, L, Kebriaei, P, Champlin, R, Giralt, S. Phase I/Ii Study Of Low-Dose Gemtuzumab Ozogamicin (GO), Fludarabine And Melphalan (Fm) Conditioning Regimen For Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In AML/MDS. Blood 104(11):505a, 2004.
  • Qazilbash M H, Wieder E, Rios R, Kant S, Lu S, Wang C, Molldrem J,. PR1 Vaccine – Induced Immunological and Clinical responses in Myeloid malignancies. Fourth International Workshop on Haploidentical Transplants, Naples, Italy, 2004.
  • Qazilbash, M, Saliba, R, de Lima, M, Couriel, D, Hosing, C, Aleman, A, Lei, X, Champlin, R, Giralt, S. Second Autologous Or Allogeneic Transplantation After The Failure Of First Autograft In Multiple Myeloma. Blood 104(11):909a, 2004.
  • Champlin, R, Ghosh, S, McCormick, G, Andersson, B, de Lima, M, Anderlini, P, Qazilbash, M, Sergio Giralt, S, Cortes, J. Sequential Treatment With Reduced Intensity Allogeneic Stem  Cell Transplantation And Imatinib For Chronic Myelogenous Leukemia (Cml): Three Chances For Cure. Blood 104(11):232a, 2004.
  • Qazilbash, M, Wieder, E, Rios, R, Lu, S, Kant, S, Giralt, S, Estey, E, Thall, P, de Lima, M, Couriel, D, Champlin, R, Komanduri, K, Molldrem, J. Vaccination With The PR1 Leukemia-Associated Antigen Can Induce Complete Remission In Patients With Myeloid Leukemia. Blood 104(11):77a, 2004.
  • Couriel DR, Hosing C, Saliba R, Shpall EJ, Anderlini P, Rhodes B, Smith V, Khouri I, Giralt S, de Lima M, Hsu Y, Ghosh S, Neumann J, Andersson B, Qazilbash M, Hymes S, Kim S, Champlin R, Donato M. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood. 107(8):3074-80, 12/2005.
  • Qazilbash MH, Kebriaei P, Saliba R, Ma C, Ippoliti C, Couriel D, de Lima M, Giralt S,Gajewski J, Ha C, Champlin R, Khouri I. Allogeneic Transplantation after an Alemtuzumab-Containing Myeloablative conditioning Regimen for CD52 Positive Acute Lymphoblastic Leukemia. Blood, 2005.
  • Qazilbash MH, Davis MS, Aleman A, Ronden L, Libunao F, Thall P, Wang X, Couriel D, de Lima M, Hosing C, Kebriaei P, Weber D, Wang M, Jones R, Matthes S, Champlin R, Giralt S. Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan: A new Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Blood, 2005.
  • Qazilbash MH, Saliba R, Aleman A, Roden L, de Lima M, Couriel D, Hosing C, Kebriaei P, Champlin R, Giralt S. Arsenic trioxide with ascorbic acid and high-dose melphalan: a new preparative regimen for autologous hematopoietic stem cell transplantation for multiple myeloma, 2005.
  • Jones J A, Qazilbash M H, Shih Y T, Cantor S B, Cooksley C D, Elting L S. Economic implication of outcomes complicating hematopoetic stem cell transplant (HSCT) for multiple myeloma (MM), Hodgkin’s (HD) and non-Hodgkin’s lymphoma (NHL). J Clin Oncol 23(16S):531s, 2005.
  • Qazilbash MH, Hosing C, Kebriaei P, Giralt S, Davis M, Rhodes B, Smith V, Shpall E, McMannis J, Korbling M, Champlin R. Fixed-Dose Single Agent Pegfilgrastim for Peripheral Blood Progenitor Cell Mobilization in Patients with Multiple Myeloma, 2005.
  • Qazilbash MH,Couriel D, Thall P, Mickler K, de Lima M, Giralt S,Hosing C, Khouri I, Kebriaei P, Hsu Y, Saliba R, Ippoliti C, Champlin R. Phase II/III Randomized study comparing two different Tacrolimus Blood Levels for the Prevention of Graft-Versus-Host Disease. Blood, 2005.
  • Qazilbash MH,Couriel D, Thall P, Mickler K, de Lima M, Giralt S,Hosing C, Khouri I, Kebriaei P, Hsu Y, Saliba R, Ippoliti C, Champlin R. Phase II/III Randomized study comparing two different Tacrolimus Blood Levels for the Prevention of Graft-Versus-Host Disease. Blood, 2005.
  • Qazilbash MH, Qu Z, Hosing C, Couriel D, Donato M, Giralt S, Champlin R. Rituximab-induced acute liver failure after an allogeneic transplantation for Chronic Myeloid Leukemia. Blood, 2005.
  • Qazilbash MH, Kebriaei P, Saliba R, Ma C, Ippoliti C, Couriel DR, de Lima M, Giralt S. The Impact of Rituximab in the Development of Acute Graft Versus Host Disease following Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia, 2005.
  • Kebriaei P, Saliba RM, Ma C, Ippoliti C, Couriel DR, de Lima M, Giralt S, Qazilbash MH, Gajewski JL, Ha CS, Champlin RE, Khouri IF. Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia. Bone Marrow Transplant. 38(3):203-9. e-Pub 6/2006.
  • Hosing C, Qazilbash MH, Kebriaei P, Giralt S, Davis MS, Popat U, Anderlini P, Shpall EJ, McMannis J, Körbling M, Champlin RE. Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma. Br J Haematol. 133(5):533-7, 6/2006.
  • Qazilbash MH, Saliba RM, Aleman A, Lei X, Weber D, Carrasco A, Champlin RE, Giralt SA. Risk factors for relapse after complete remission with high-dose therapy for multiple myeloma. Leuk Lymphoma. 47(7):1360-4, 7/2006.
  • Kurian S, Qazilbash M, Fay J, Wolff S, Herzig R, Hobbs G, Bunner P, Weisenborn R, Aya-Ay M, Lynch J, Ericson S. Complete response after high-dose chemotherapy and autologous  hemopoietic stem cell transplatation in metastatic breast cancer results in survival benefit. British Journal 12(6):531-5, 11/2006.
  • Qazilbash MH,Libunao F, Ronden L, Davis M, Champlin R, Giralt S. Arsenic Trioxide in combination with Ascorbic Acid and High-Dose Melphalan is Safe for Patient with MM Undergoing an Autologous Transplan. Biology of Blood and Marrow Transplantation, 2006.
  • Qazilbash MH, Saliba R, Davis M, Mendoz F, Hosing C, Couriel D, De Lima M, Kebriaei P, Weber D, Wang M, Alousi A, Matthes S, Jones R, Champlin R, Giralt S. Arsenic Trioxide with Ascorbic Acid and High-Hose Melphalan for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myleoma. ASH Annual Meeting Abstracts, 2006.
  • Qazilbash MH, Saliba, R, Hosing C, Mendoza F, Qureshi S, Weber D, Wang M, Flosser T, Couriel D, DeLima M, Kebriaei P, Alousi A, Champlin R, Giralt S. Autologous Stem Cell Transplantation for Elderly Multiple Myeloma. ASH Annual Meeting Abstracts, 2006.
  • Qazilbash MH,Ahmed B, Saliba R, Ashraf N, Mendoza F, Hosing C, Flosser T, Weber D, Wang M, Couriel D, Popat U, Kebriaei P, Alousi A, Champlin R, Giralt S. Deletion of the Short Arm of Chromosome 1 (del 1p) Is the Strongest Predictor of Poor Outcome in Myeloma Patients Undergoing an Autotransplant. ASH Annual Meeting Abstracts, 2006.
  • Qazilbash MH,Khouri I, Saliba R, Hosing C, Valverde R, Erwin W, Fayad L, Maadani F, Korbling M, Okoroji G, Stachowiak A, Samuels B, Anderlini P, Couriel D, De Lima M, Giralt S, Popat U, Kebriaei P, Ueno N,McLaughlin P, Gagemeister F, Youn A, Podoloff D, Champlin R. Efficacy and Safety of Yttrium 90 (90Y) Ibritumon Tiuxetan in Autologous and Nonmyeloablative Stem Cell Transplantation (NST) for Relapsed Non-Hodgkin’s Lymphoma (NHL). ASH Annual Meeting Abstracts, 2006.
  • Qazilbash MH,Hosing C, Saliba R, Okoroji G, Popat U, Couriel D, Kebriaei P, Ali T, De Lima M,Anderlini P, Giralt S, Champlin R, Khouri I. High-Dose Chemotherapy and Autologous hematopoietic Progenitor Cell Transplantation (AHCT) for Non-Hodgkin’s Lymphoma (NHL) in Patients over 65 Years of Age. ASH Annual Meeting Abstracts, 2006.
  • Qazilbash MH, Kebriaei P, Madden TL, Thapar L, Shpall EJ, Hosing C,De Lima M, Thall PF, Wright S, Khouri IF. Intravenous (i.v.) busulfan (Bu) plus melphalan (Mel) is a well-tolerated preparative regimen for stem cell transplantation (SCT) in patients (pts) with advanced lymphoid malignancies. Biology of Blood and Marrow Transplantation, 2006.
  • Qazilbash MH, Kebriaei P, Madden T, Thapar N, Shpall E, Hosing C, Thall P, Khouri I, Champlin R, Jones R, Andersson B. Intravenous (i.v.) busulfan (Bu) plus melphalan (Mel) is a well-tolerated preparative regimen for Stem Cell Transplantation (SCT) in patients (pts) with advanced lymphoid malignancies,. ASCO Meeting Abstracts, 2006.
  • Qazilbash MH, Soriano A, Champlin R, McCormick, Giralt S, Thall P, Komanduri K,Garcia-Manero G, De Lima M. Maintenance Therapy with 5-Azacytidine (5-AC) after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic (MDS): A Dose and Schedule Finding Study. ASH Annual Meeting Abstracts, 2006.
  • Qazilbash MH, Rios R, Thall P, Wang X, Wider E, Lu S, Kant S, Giralt S, Estey E, Cortes j, Champlin R, Komanduri K, Molldrem J. PR1 Vaccine after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2006.
  • Qazilbash MH, De Souza J, Saliba R, Patah P, Rondon G,Popat U, Champlin R, De Lima M. Renal Function Impairment and Outcomes of Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation. ASH Annual Meeting Abstracts, 2006.
  • Qazilbash MH, Saliba R, Mendoza F, Ronden L, Hosing C, Couriel DR, Kebriaei P, Popat U, de Lima M, Champlin RE, Giralt SA. Salvage non-myeloablative allogeneic transplantation after failure of an autologous transplantation in multiple myeloma. Biology of Blood and Marrow Transplantation, 2006.
  • Qazilbash MH,Kebriaei P, Giralt S, Madden T, Thapar N, Sphall E, Hosing C, Couriel D, Popat U. Thall P, Champlin R, Jones R, Andersson B. Toxicity and Early Response after Intravenous (IV) Busulfan (Bu) Plus Melphalan (Mel) Conditioning for Autologous Stem Cell Transplantation (SCT) in Patients (pts) with Multiple Myeloma (MM). ASH Annual Meetings Abstracts, 2006.
  • Oran B, Giralt S, Saliba R, Hosing C, Popat U, Khouri I, Couriel D, Qazilbash M, Anderlini P, Kebriaei P, Ghosh S, Carrasco-Yalan A, de Meis E, Anagnostopoulos A, Donato M, Champlin RE, de Lima M. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant 13(4):454-62, 2/2007. e-Pub.
  • Qazilbash MH, Jindani S, Gul Z, Saliba R, Hosing C, Mendoza F, Qureshi SP, Weber DM, Wang M, Flosser T, Couriel DP, Kebriaei P, Popat U, Alousi AM, de Lima M, Champlin RE, Giralt. Arsenic trioxide with ascorbic acid and high-dose melphalan for autologous hematopoietic stem cell transplantation for multiple myeloma. Biology of Blood and Marrow Transplantation 13(2):9-10, 2/2007.
  • Qazilbash MH, Gul Z, Jindani S, Saliba R, Hosing C, Mendoza F, Qureshi SP, Weber DM, Wang M, Flosser T, Couriel DP, de Lima M, Kebriaei P, Popat U, Alousi AM, Champlin RE, Giralt SA. Autologous stem cell transplantation for elderly patients with multiple myeloma. Biology of Blood and Marrow Transplant 13(2):10, 2/2007.
  • Christoforidou AV, Saliba RM, Williams P, Qazilbash M, Roden L, Aleman A, Weber D, Mendoza F, Podoloff D, Wendt R 3rd, Breitz H, Alexanian R, Champlin R, Giralt S. Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes. Biol Blood Marrow Transplant 13(5):543-9, 2/2007. e-Pub.
  • Saliba RM, de Lima M, Giralt S, Andersson B, Khouri IF, Hosing C, Ghosh S, Neumann J, Hsu Y, De Jesus J, Qazilbash MH, Champlin RE, Couriel DR. Hyperacute GVHD: risk factors, outcomes, and clinical implications. Blood. 109(7):2751-8, 4/2007.
  • Popat UR,de Lima M,Anderlini P,Andersson B,Couriel D,Hosing C,Kebriaei P,Qazilbash MH,Alousi A,Champlin R,Giralt S. Long-term survival of patients with AML in remission after reduced intensity allogeneic hematopoietic stem cell transplantation (RISCT). Journal of Clinical OncologyJournal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Vol 25, No. 18S (June 20 Supplement), 2007 (#7002), 6/2007.
  • Qureshi S,Bukhari F,Saliba RM,Hosing C,Champlin RE,Giralt SA,De Lima MJ,Yusuf SW,Qazilbash, MH. Outcome of allogenic SCT in patients with low left ventricular ejection fraction. Journal of Clinical Oncology,2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement (#7099), 6/2007.
  • Ozdemir E, Saliba RM, Champlin RE, Couriel DR, Giralt SA, de Lima M, Khouri IF, Hosing C, Kornblau SM, Anderlini P, Shpall EJ, Qazilbash MH, Molldrem JJ, Chemaly RF, Komanduri KV. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant. 40(2):125-36, 7/2007. e-Pub 5/2007.
  • Qazilbash MH, Saliba RM, Ahmed B, Parikh G, Mendoza F, Ashraf N, Hosing C, Flosser T, Weber DM, Wang M, Couriel DR, Popat U, Kebriaei P, Alousi AM, Anderlini P, Naeem RC, Champlin RE, Giralt SA. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. Biol Blood Marrow Transplant. 9:1066-72, 9/2007. e-Pub 7/2007.
  • de Lima M, Padua L, Giralt SA, CHosing C, Komanduri K, Qazilbash MH, Shpall EJ, Thall P, Qureshi S, McCormick G, Tong W, Popat U, Soriano A, Champlin RE, Manero GG. A Dose and Schedule Finding Study of Maintenance Therapy with Low-Dose 5-Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for High-Risk AML or MDS. Blood (ASH Annual Meeting Abstracts) 110 (#3012), 2007.
  • Qazilbash MH, Saliba RM, Parikh GC, Hosing C, Mendoza F, Weber DM, Wang M, Thomas SK, Flosser TS, Kebriaei P, Popat U, Alousi AM, de Lima M, Champlin RE, Giralt SA. A Non-Myeloablative Regimen of Fludarabine and Melphalan Is Safe and Well Tolerated for Allogeneic Transplantation in Multiple Myeloma. Blood (ASH Annual Meeting Abstracts). 2007 110 (#3032), 2007.
  • Qazilbash MH, Saliba RM, Parikh G, Hosing F, Mendoza F, Qureshi SP, Weber DM, Wang M, Flosser T, Couriel DR, Kebriaei P,Popat UR,Alousi A,de Lima M,Champlin RE, Giralt S. Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan Is Safe and Effective for Autotransplantation for Multiple Myeloma. Blood (ASH Annual Meeting Abstracts). 2007 110 (#942), 2007.
  • Parikh GC, Saliba RM, Lahoti A, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Popat UR, Alousi AM, Champlin RE, Giralt SA, Qazilbash MH. Autotransplantation in Patients with Multiple Myeloma and Concurrent Renal Failure Is Safe and Feasible and Associated with Recovery of Renal Function in > 30% of Patients. Blood (ASH Annual Meeting Abstracts). 2007 110 (#5126), 2007.
  • Chu DT, Saliba R, Qureshi S, Alousi A, Anderlini P, Bukhari F, Delima M, Giralt SA, Kebriaei P, Khouri IF, Parikh G, Popat U, Shpall EJ, Yusuf WS, Champlin RE, Qazilbash MH, Hosing C. Cardiac Toxicity and Non-Relapse Mortality in Patients with Low Left Ventricular Ejection Fraction Undergoing Stem Cell Transplantation. Blood (ASH Annual Meeting Abstracts). 2007 110 (#3002), 2007.
  • Hosing C, Munsell M, Popat U, Körbling M, Valverde R, Maadani F, Kebriaei P, Alousi A, DeLima M, McMannis J, Shpall EJ, Qazilbash MH, Anderlini P, Giralt S, Champlin RE, Khouri I. Chemotherapy with Granulocyte Colony Stimulating Factor (G-CSF) Alone Versus Granulocyte Colony Stimulating Factor (G-CSF) Plus Granulocyte-Macrophage Stimulating Factor (GM-CSF) for Hematopoietic Progenitor Cell Mobilization in Patients with Relapsed Non-Hodgkin’s Lymphomas (NHLs). Blood (ASH Annual Meeting Abstracts). 2007 110 (#1900), 2007.
  • Popat UR, Rondon G, Alousi AM, Anderlini P, Andersson BS, de Lima MJ, Giralt SA, Hosing CM, Kebriaei P, Jones RB, Nieto YL, Shpall EJ, Verstovesek S, Qazilbash MH, Champlin RE. Myelofibrosis and Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation (RISCT). Blood (ASH Annual Meeting Abstracts). 2007 110 (#3062), 2007.
  • Leandro De Padua Silva, Donna Weber, Michael Wang, Eric Han, Floralyn Mendoza, Marcos de Lima, Muzaffar Qazilbash, Richard E. Champlin, and Sergio Giralt. Myeloma with AL Amyloidosis: 10 Years Experience with Stem Cell Transplant. Blood (ASH Annual Meeting Abstracts). 2007 110 (#5112), 2007.
  • Champlin RE, Giralt SA, Shpall EJ, Kebriaei P, Anderlini P, Qazilbash MH, McMannis J, McCormick G, Fisher T, de Lima M, Rondon G. Nonmyeloablative Allogeneic Transplantation in the Imatinib Era: Three Chances To Achieve Molecular Remission in CML. Blood (ASH Annual Meeting Abstracts). 2007 110 (#1028), 2007.
  • Silva LD, Saliba RM, de Lima M, Okoroji GJ, Alousi A, Andersson B, Hosing C, Sphall EJ, Khouri I, Qazilbash MH, Anderlini P, Kebriaei P, Champlin RE, Jones RB, Giralt SA, Popat U. Obesity Does Not Impact Outcome in Patients with AML/MDS Undergoing Allogeneic Transplantation. Blood (ASH Annual Meeting Abstracts). 2007 110 (#1989), 2007.
  • Qazilbash MH, Wieder ED,Thall PF,Wang X, Rios RL,Lu S,Kant S, Giralt S, Estey EH,Cortes J,Komanduri K,Champlin RE,Molldrem JJ. PR1 Peptide Vaccine-Induced Immune Response Is Associated with Better Event-Free Survival in Patients with Myeloid Leukemia. Blood (ASH Annual Meeting Abstracts) 2007 110 (#283), 2007.
  • Qazilbash MH, Wieder ED, Thall PF, Wang X,Rios RL, Lu S, Kant S, Giralt SA, Estey EH, Cortes J,Komanduri K,Champlin RE,Molldrem JJ,. PR1 Vaccine Elicited Immunological Response after Hematopoietic Stem Cell Transplantation Is Associated with Better Clinical Response and Event-Free Survival. Blood(ASH Annual Meeting Abstracts) 2007 110 (#577), 2007.
  • Giralt SA, Saliba RM, Mendoza F, Parikh G, Qureshi S, Zhang W, Popat U, Qazilbash MH, Khouri I, Hosing C, Alousi A, Anderlini P, Andersson B, Jones RB, Shpall EJ, Kebriaei P, Nieto YL, Ueno N, Champlin RE, de Lima M. Pre Transplant Values of C Reactive Protein (CRP) and Brain Natriuretic Peptide (BNP) as Predictors of Transplant Outcomes in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndromes (AML/MDS) Undergoing Allogeneic Stem Cell Transplantation (AlloSCT). Blood (ASH Annual Meeting Abstracts). 2007 110 (#1984), 2007.
  • de Lima M, Andersson B, Fernadez-Vina M, Giralt SA, Couriel D, Shpall EJ, Popat UR, Qazilbash MH, Alousi A, Cano P, Bosque D, Hosing C, Qureshi S, de Padua L, Munsell M, Anderlini P, Jones RB, Westmoreland M, Gulbis A, Champlin RE. Prophylaxis of Graft-Versus-Host Disease (GVHD) with Pentostatin, Tacrolimus, and "Mini"-Methotrexate (MTX): A Phase I/II Controlled, Randomized Study in Unrelated Donor (UD) Transplantation. Blood (ASH Annual Meeting Abstracts). 2007 110 (#40), 2007.
  • Giralt SA, Thandi R, Qazilbash MH, Mendoza F, Han E, Hosing C, Wang M, Thomas S, Alexanian R, Champlin RE, Weber D. Retrospective Comparison of Transplant Outcomes in Patients with Multiple Myeloma According to Induction Therapy with Thalidomide/Dexamethasone (TD) with or without Bortezomib (VTD). Blood (ASH Annual Meeting Abstracts). 2007 110 (#948), 2007.
  • Westin JR, Saliba RM, de Lima M, Alousi AM, Hosing C, Qazilbash MH, Khouri IF, Shpall EJ, Champlin RE, Couriel DR. Risk Factors for Response after Initial Therapy for Acute Graft-Versus-Host-Disease (aGVHD). Blood (ASH Annual Meeting Abstracts). 2007 110 (#5015), 2007.
  • Anderlini P, Saliba R, Acholonu S, Giralt SA, Andersson B, Ueno NT, Hosing C, Khouri IF, Couriel D, de Lima M, Qazilbash MH, Pro B, Romaguera J, Fayad L, Hagemeister F, Younes A, Munsell MF, Champlin RE. Fludarabine-melphalan as a preparative regimen for. Haematologica 93(2):257-64 (#11828), 2/2008. e-Pub 1/2008.
  • Popat U, Saliba R, Ablawat S, Okoroji GJ, Alousi A, Anderlini P, Andersson B, de Lima M, Jones R, Kebriaei P, Korbling M, Nieto Y, Qazilbash M, Shpall EJ, Khouri I, Giralt S, Champlin R, Hosing C. Incidence And Factors Influencing Stem Cell Mobilization In Patients With Non-Hodgkin's Lymphoma (NHL) And Hodgkin's Disease (HD). Biology of Blood and Marrow Transplantation 14(2):37 (#96), 2/2008.
  • Williams LA, Giralt SA, Mendoza TR, Andersson KO, Mobley GM, Saliba RM, Qazilbash MH, Campagnaro EL, Cleeland CS. Larger Stem Cell Dose Is Associated With Decreased Symptom Severity After Autologous Stem Cell Transplantation For Multiple Myeloma. Biology of Blood and Marrow Transplantation 14(2):98 (#267), 2/2008.
  • Silva L, Weber D, Wang M, Han E, Mendoza F, de Lima M, Qazilbash M, Champlin RE, Giralt S. Myeloma With AL Amyloidosis: 10 Years Experience With Stem Cell Transplant. Biology of Blood and Marrow Transplantation 14(2):36 (#91), 2/2008.
  • Ramos CA, Saliba RM, Giralt S, Khorshid O, de Padua L, Andersson BS, Nieto YL, Popat UR, Qazilbash MH, Qureshi S, Zhang W, Champlin RE, de Lima M. The Impact of Resolved Hepatitis B Infection on Allogeneic Hematopoietic Stem Cell Transplantation For Hematological Malignancies. Biology of Blood and Marrow Transplantation 14(2):8 (#15), 2/2008.
  • Qazilbash MH, Saliba RM, Pelosini M, Hosing CM, Mendoza FL, Han E, Wang M, Weber DM, Alousi AM, Anderlini P, Kebriaei P, Khouri IF, Popat UR, De Lima M, Orlowski RZ, Champlin RE, Giralt SA. A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 2008 112(11):1140 (#3320), 11/2008.
  • Kebriaei P, Giralt S, Jones D, Gutierrez K, De Lima M, Korbling M, Khouri IF, Popat U, Qazilbash MH, Alousi A, Ciurea SO, Cooper L, Shpall E, Champlin R. Addition of Umbilical Cord Blood (UCB) Unit to Reduced Intensity Conditioning (RIC) Regimen to Augment Graft Versus Tumor (GVT) in Patients (pts) with Advanced Hematologic Malignancies. Blood (ASH Annual Meeting Abstracts) 2008 112(11):1132 (#3297), 11/2008.
  • Ciurea SO, De Lima M, Giralt M, Qazilbash MH, Alousi A, Kebriaei P, Khouri IF, Anderlini P, Andersson B, Hosing C, Verstovsek S, Kantarjian H, Champlin R, Popat U. Allogeneic Stem Cell Transplantation for Patients with Acute Leukemia Transformed from Myelofibrosis. Blood (ASH Annual Meeting Abstracts) 2008 112(11):1131 (#3293), 11/2008.
  • Popat U, De Lima MJ, Ativitavas T, Rondon G, de Padua Silva L, Koca E, Zhang W, Alousi A, Anderlini P, Giralt SA, Hosing CM, Jones R, Kebriaei P, Khouri I, Nieto Y, Qazilbash MH, Andersson BS, Champlin RE. Allogeneic Transplantation (HCT) for Myelodysplastic Syndrome:Recent MDACC Experience. Blood (ASH Annual Meeting Abstracts) 2008 112(11):413 (#1131), 11/2008.
  • Hosing C, Smith VR, Rhodes BA, Walters KH, Qazilbash MH, McMannis JD, Alousi AM, De Lima M, Kebriaei P, Giralt S, Khouri I, Champlin R, Popat U. An Analysis of the Costs Associated with Peripheral Blood Hematopoietic Progenitor Cell Mobilization, Collection and Cryopreservation in Patients with Lymphomas Undergoing Autologous Stem Cell Transplantation. Blood (ASH Annual Meeting Abstracts) 2008 112(11):828 (#2377), 11/2008.
  • Popat U, Saliba R, de Padua Silva L, Andersson BS, Alousi AM, Anderlini P, de Lima M, Okoroji GJ, Hosin CM, Jones RB, Kebriaei P, Khouri I, Nieto Y, Qazilbash MH, Chanmplin R, Giralt S. Busulfan and Fludarabine Conditioning Regimen Negates the Impact of Comorbidity Score on Nonrelapse Mortality in Patients with AML/MDs. Blood(ASH Annual Meeting Abstracts) 2008 112(11):297 (#799), 11/2008.
  • De Lima M, McMannis JD, Saliba R, Worth L, Kebriaei P, Popat U, Qazilbash M, Jones R, Giralt S, de Padua Silva L, Cooper L, Petropoulos D, Lee D, Kelly S, Thall P, Robinson S, Khouri I, Hosing C, Korbling M, Alousi A, Rondon G, Andersson BS, Nieto Y, Ciurea S, Komanduri K, Champlin RE, Shpall E. Double Cord Blood Transplantation (CBT) with and without Ex-Vivo Expansion (EXP): A Randomized, Controlled Study. Blood (ASH Annual Meeting Abstracts) 2008 112(11):63 (#154), 11/2008.
  • Ciurea SO, Kebriaei P, Khouri IF, Qazilbash MH, Jones RB, Petropoulos D, Worth LL, Alousi AM, Hosing CM, Patah P, Cano P, McMannis J, Giralt SA, Fernandez-Vina M, Champlin RE, Shpall EJ, De Lima M. High Rate of Engraftment and Low Regimen-Related Toxicity Using Fludarabine, Melphalan and Thiotepa Conditioning for Unrelated Donor Cord Blood Transplantation. Blood (ASH Annual Meeting Abstracts) 2008 112(11) (#4414), 11/2008.
  • Kazmi S MA, Mendoza FL, Weber D, Wang ML, Hosing C, Khouri IF , Anderlini P, De Lima M, Kebriaei P, Popat UR, Champlin RE, Giralt SA, Qazilbash MH. High-Dose Topotecan, Melphalan and Cyclophosphamide (TMC) with Autologous Stem Cell Support for Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 2008 112(11) (#4452), 11/2008.
  • Jabbour E, De Lima M, de Padua Silva L, Giralt S, Cortes J, Qazilbash M, Rondon G, Ciurea S, Jones R, Nieto Y, Korbling M, Couriel D, Kantarjian H, Champlin R. Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Patients (pts) with Advanced Chronic Myeloid Leukemia (CML) Post Imatinib Failure. Blood (ASH Annual Meeting Abstracts) 2008 112(11):360 (#979), 11/2008.
  • De Lima M, de Padua Silva L, Giralt S, Komanduri K, AnderssonBS, Hosing C, Qazilbash M, Shpall E, Thall P, Zhang W, McCormick G, Wang X, Popat U, Soriano A, Alousi A, Champlin R, Garcia-Manero G. Maintenance Therapy with Low-Dose Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed or Refractory AML or MDS: A Dose and Schedule Finding Study. Blood (ASH Annual Meeting Abstracts) 2008 112(11):414 (#1134), 11/2008.
  • Khouri IF, Lopez A, Okoroji GJ, Korbling M, McCormick G, Hsu Y, de Padua Silva L, Alousi AM, Hosing CM, Kebriaei P, Rondon G, Giralt SA, de Lima MJ, Anderlini P, Popat UR, Qazilbash MH, Champlin RE, Pro B. Myeloablative Chemotherapy for T-Cell Lymphoma: a Case for Autologous Stem Cell Transplantatin (Auto) in First Remission. Blood (ASH Annual Meeting Abstracts) 2008 112(11):417 (#1141), 11/2008.
  • Alatrash G, Andersson BS, Pelosini M, Rondon G, Qazilbash MH, Giralt S, de Padua Silva L, Hosing C, Kebriaei P, Zhang W, Saliba R, Champlin RE, De Lima M. Myeloablative, Reduced Toxicity IV Busulfan/Fludarabine (BuFlu) and Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Patients in the 6th and 7th Decades of Life with AML or MDS. Blood (ASH Annual Meeting Abstracts) 2008 112(11):1031 (#2999), 11/2008.
  • de Padua Silva L, Cortes J, Jabbour E, Giralt S, Kebriaei P, O'Brien S, Alousi A, Qazilbash M, Rondon G, Ravandi F, Ribeiro R, Hosing C, Kantarjian H, Champlin R, De Lima M. Novel Tryosine Kinase Inhibitor Threapy Before Allogeneic Stem Cell Transplantation in Patients with Chronic Myeloid Leukemia. Blood (ASH Annual Meeting Abstracts) 2008 112(11):750 (#2154), 11/2008.
  • Khan ZU, Saliba RM, Qureshi S, Hosing C, Giralt SA, De Lima MJ, Yusuf SW, Popat UR, Champlin RE, Qazilbash MH. Outcome of Allogeneic Stem Cell Transplantation in Patients with Low Ventricular Ejection Fraction. Blood (ASH Annual Meeting Abstracts) 2008 112(11):1135 (#3306), 11/2008.
  • Khouri I, Bassett RL, Hsu Y, Dickason T, Acholonu S, Harrell R, Okorji GJ, de Padua Silva L, Korbling MJ, Alousi AM, Hosing C, Popat U, Giralt SA, Kebriaei P, Qazilbash MH, Ledesma C, Keating MJ, Champlin RE, Bueso-Ramos C. Prognostic Factors after Nonmyeloablative Allogeneic Stem Transplantation (NST) in Chronic Lymphocytic Leukemia (CLL): Expression of P53 May Not Predict Survival. Blood (ASH Annual Meeting Abstracts) 2008 112(11):412 (#1128), 11/2008.
  • de Padua Silva L, Saliba RM, Giralt S, De Lima M, Hosing C, Khouri IF, Popat U, Qazilbash M, Shpall E, Thomas DA, Kantarjian H, Champlin R, Kebriaei P. Reduced Intensity Conditioning (RIC) Regimen Followed by Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Adult Patients with Acute Lymphoblastic Leukemia (ALL). Blood (ASH Annual Meeting Abstracts) 2008 112(11) (#4326), 11/2008.
  • Cole SM, Saliba R, Pelosini M, Mendoza FL, Weber D, Wang M, Thomas S, Orlowski RZ, Shah J, Alousi A, Hosing C, Popat U, Kebriaei P, Anderlini P, Khouri IF, Champlin R, Giralt S, Qazilbash MH. Reduced-Intensity Regimens for Allogeneic Stem Cell Transplantation Improve the Outcome in Advanced Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 2008 112(11):1132 (#3298), 11/2008.
  • Tam CS, bassett R, Ledesma C, Korbling MJ, Okoroji GJ, Harrell R, Hsu Y, De Padua Silva L, Alousi AM, Hosing CM, Kebriaei P, Rondon G, Giralt S, De Lima M, Anderlini P, Popat U, Qazilbash MH, Samuels B, Champlin RE, Khouri I. Rituximab Containing Autologous Stem Cell Transplantation May Be Curative in Mantle Cell Lymphoma for Patients in First Remission, but Not for Patients with Recurrent Disease. Blood (ASH Annual Meeting Abstracts) 2008 112(11):417 (#1142), 11/2008.
  • Koca E, Parikh G, Amjad AI, Mendoza FL, Hosing CM, Popat U, Champlin RE, Giralt S, Qazilbash MH. Role of Brain-Type Natriuretic Peptide and Cardiac Troponins as Predictors of Outcome in Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 2008 112(11) (#4457), 11/2008.
  • Alatrash G, Andersson B, Pelosini M, Rondon G, Qazilbash M, Giralt S, de Padua S, Hosing C, Kebriaei P, Zhang W, Saliba R, Champlin R, de Lima M. Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Patients In the 6th and 7th Decades Of Life With AML OR MDS Using Myeloablative, Reduced Toxicity IV Busulfan/Fludarabine (BUFLU) Conditioning Regimen. ASBMT (Annual Meeting Abstracts) 2009 15(2(2)):106 (#293), 2/2009.
  • de Padua Silva L, Saliba RM, Giralt S, de Lima M, Hosing C, Khouri IF, Popat U, Qazilbash M, Shpall E, Thomas DA, Kantarjian H, Champlin R, Kebriaei P. Reduced Intensity Conditioning (RIC) Regimen Followed by Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Adult Patients with Acute Lymphoblastic Leukemia (ALL). ASBMT (Annual Meeting Abstracts) 2009 15(2(2)):62 (#169), 2/2009.
  • Sharma M, Thall P, Wang X, Hosing C, Mendoza FL, Han E, Wang M, Weber D, Shah J, Alousi A, Anderlini P, Kebriaei P, Khouri I, Popat U, de Lima M, Champlin RE, Giralt S, Qazilbash M. A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma. Blood (Ash Annual Meeting Abstracts) 114(22):912 (#2309), 11/2009.
  • Popat U, Rondon G, Alousi A, Anderlini P, Andersson B, Hosing C, de Lima M, Ciurea S, Giralt S, Kebriaei P, Nieto Y, Khouri I, Qazilbash MH, Jones R, Champlin R. Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis. Blood (ASH Annual Abstracts) 114(22):900 (#2283), 11/2009.
  • De Padua Silva L, Saliba R, McCormick D, Okoroji GJ, Alousi A, Anderlini P, Ciurea S, Hosing C, Kebrieai P, Popat U, Qazilbash M, Ueno N, McMannis J, Champlin R, Pro B, Khouri I. Autologous Stem Cell Mobilization with Cytokines and in-Vivo Alemtuzumab in Patients with T-Cell Non-Hodgkin's Lymphoma (T-NHL). Blood (ASH Annual Abstracts) 114(22):1245 (#3213), 11/2009.
  • Popat U, Hosing C, Fanale M, Mederios J, Alousi AM, Giralt SA, de Lima M, Qazilbash MH, Kebrieai P, Younes A, Khouri I, Andersson B, Champlin R, Anderlini P. Autologous Transplantation for Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). Blood (ASH Annual Abstracts) 114(22):912 (#2310), 11/2009.
  • Alousi AM, Rondon G, Okoroji GJ, Popat U, De Padua Silva L, Hymes S, Neumann J, Brunelle NM, Kebrieai P, Hosing C, Khouri IF, Shpall EJ, Qazilbash MH, Giralt S, Champlin R, Saliba RM. Co-Morbidity Score at the Time of Transplant Determines Prognosis in Older Patients Who Develop Acute Graft-Vs.-Host Disease (GVHD). Blood (ASH Annual Abstracts) 114(22):884 (#2244), 11/2009.
  • Shah N, Ahmed KF, Qureshi S, Shah J, Orlowski RZ, Weber DM, Hosing C, Popat U, Alousi A, Champlin RE, Giralt S, Qazilbash M. Durable Remission with Salvage Autotransplants in Patients with Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 114(22):506 (#1227), 11/2009.
  • Kebrieai P, Madden T, Kazerooni R, Shpall E, Wang X, Thall P, Hosing C, Qazilbash M, Popat U, Ledesma C, Khouri I, Champlin R, Jones R, Andersson BJ. Intravenous Busulfan Plus Melphalan Is a Highly Effective, Non-Toxic Preparative Regimen for Autologous Stem Cell Transplantation (ASCT) in Patients with Advanced Lymphoid Malignancies. Blood (ASH Annual Abstracts) 114(22):1326 (#3415), 11/2009.
  • Qureshi S, Sharma M, Hosing C, Mendoza FL, Shah J, Alousi A, Anderlini P, Kebrieai P, Khouri IF, Popat U, de Lima M, Champlin RE, Giralt S, Qazilbash MH. Outcome of IgD Myeloma After Autologous Hematopoietic Stem Cell Transplantation. Blood (ASH Annual Meeting) 114(22) (#4354), 11/2009.
  • Bashir Q, Thall P, Hosing C, Mendoza FL, Han E, Wang M, Shah J, Alousi A, Anderlini P, Kebriaei P, Khouri IF, Popat U, de Lima M, Champlin R, Giralt S, Qazilbash MH. Salvage Autologous or Allogeneic Stem Cell Transplantation After the Failure of First Autograft in Patients with Multiple Myeloma. Blood (ASH Annual Abstracts) 114(11):487 (#1186), 11/2009.
  • Khouri IF, Harrell R, Valverde R, Korbling M, Manshouri T, Samuels B, Maadani F, Okoroji GJ, Bassett Jr. RL, Alousi A, Anderlini P, de Lima M, Giralt S, Hosing C, Kebriaei P, Popat U, Qazilbash M, Ueno N, Stachowiak AM, Erwin B, Fayad L, Pro B, Fowler N, McLaughlin P, Neelapu S, Younes A, Champlin R, Podoloff D. Stem Cell Transplantation with 90yttrium Ibritumomab Tiuxetan(90YIT) in Non-Hodgkin's Lymphoma (NHL): Observations From PET Pre-Treatment Imaging and Responses in Allografted Refractory Follicular Histologies. Blood (ASH Annual Abstracts) 114(22):354 (#868), 11/2009.
  • Shah N, Weber DM, Wang M, Thomas S, Shah J, Giralt S, Alexanian R, Orlowski RZ, Qazilbash MH, Avery T. Survival Disparities Between African-American and Caucasian Patients with Multiple Myeloma Are Blunted in the Era of Novel Therapeutics and Autologous Stem Cell Transplantation. Blood (ASH Annual Abstracts) 114(22):568 (#1395), 11/2009.
  • Bashir Q, Wei W, Chiattone A, Rondon G, Parmar S, Shah N, Booc EH, Dinh Y, Qureshi S, Shah JH, Orlowski RZ, Weber D, Champlin R, Giralt S, Qazilbash MH. Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma. Blood (ASH Annual Meeting Abstracts). 116 (#4569), 12/2010.
  • Champlin R, Lee DA, Fernandez-Vina M, Rondon G, McAdams P, Chen J, Qazilbash MH, Kebriaei P, Parmar S, Shpall EJ, Popat U, Alousi A, Ciurea SO, Cooper L, Thall P, McMannis J. Alloreactive Nk Cells to Augment Antileukemia Cytotoxicity with Allogeneic Stem Cell Transplantation for Aml/Mds: A Phase I Study. Blood (ASH Annual Meeting Abstracts) 116 (#489), 12/2010.
  • Bashir Q, Wei W, Chiattone A, Rondon G, Parmar S, Shah N, Booc EH, Dinh Y, Qureshi S, Shah JJ, Orlowski RZ, Weber D, Champlin R, Giralt S, Qazilbash MH. Autologous Hematopoietic Cell Transplantation In Multiple Myeloma Patients Age 70 Years and Older. Blood (ASH Annual Meeting Abstracts) 116 (#4576), 12/2010.
  • Nieto Y, Anderlini P, Popat U, Liu P, Andersson BS, Shpall EJ, Kebrieai P, Hosing C, Alousi AM, Qazilbash MH, Ciurea SO, Parmar S, Champlin RE, Jones R. Gemcitabine, Busulfan and Melphalan (GemBuMel) Is a New High-Dose Chemotherapy (HDC) Regimen with High Activity In Refractory Hodgkin's Lymphoma (HL) Patients Receiving An Autologous Stem-Cell Transplant (ASCT): A Contemporaneous Comparison with BEAM and Busulfan/Melphalan (BuMel). Blood (ASH Annual Meeting Abstracts). 116 (#690), 12/2010.
  • Parmar S, Khan M, Rondon G, Shah N, Bashir Q, Tung S, Shah JJ, Weber D, Orlowski RZ, Giralt S, Champlin RE, Qazilbash MH. High Dose Melphalan with Autologous Stem Cell Transplantation Overcomes Poor Prognosis of Primary Amyloidosis. Blood (ASH Annual Meeting Abstracts). 116 (#1350), 12/2010.
  • Okoroji GJ, de Padua Silva L, Saliba RM, Korbling M, McLaughlin P, Hosing C, Anderlini P, Alousi A, de Lima M, Kebriaei P, Popat U, Qazilbash M, Fayad L, Samaniego F, Fowler N, Champlin R, Hagemeister F, Khouri IF. Outcome In Follicular Lymphoma (FL) Patients (pts) Relapsing After Autologous Stem Cell Transplantation (ASCT): Allografting Vs. Conventional Therapy. Blood (ASH Annual Meeting Abstracts) 116 (#3510), 12/2010.
  • Parmar S, Khan M, Rondon G, Shah N, Bashir Q, Tung S, Shah JJ, Weber D, Orlowski RZ, Giralt S, Champlin RE, Qazilbash MH. Outcome of High Dose Melphalan with Autologous  Hematopoietic Stem Cell Transplant In Myeloma Associated with AL Amyloidosis. Blood (ASH Annual Meeting Abstracts). 116 (#2400), 12/2010.
  • Shah JJ, Orlowski RZ, Alexanian R, Wang M, Thomas S, Qazilbash MH, Parmar S, Shah N, Bashir Q, Popat U, Weber D. Phase I Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 116 (#1948), 12/2010.
  • McCarthy PL, Owzar K, Anderson KC, Hofmeister CC, Hurd DD, Hassoun H, Giralt S, Stadtmauer EA, Richardson PG, Weisdor DJ, Vij R, Moreb JS, Callander NS, Besien KV, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Hars V, Postiglione J, Jiang C, Bennett E, Barry SS, Bressler L, Kelly M, Sexton M, Rosenbaum C, Parameswaran H, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Linker C. Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104. Blood (ASH Annual Meeting Abstracts). 116 (#37), 12/2010.
  • Sharma M, Saliba RM, Qazilbash MH, Okoroji GJ, Popat U, de Lima M, Champlin R, Hosing C. Poor FEV1 or DLco on Pre-Transplant PFT Does Not Compromise Outcomes In Patients Undergoing a Reduced-Intensity Allogeneic Progenitor Cell Transplant. Blood (ASH Annual Meeting Abstracts). 116 (#1322), 12/2010.
  • Alousi AM, Andersson BS, Saliba RM, Botnick W, Rondon G, Shpall EJ, de Lima M, Popat U, Hosing C, Kebriaei P, Khouri I, Qazilbash MH, Anderlini P, Nieto Y, Ciurea S, Jones R, Champlin R. Reduced Intensity Conditioning Combined with Post-Transplant Cyclophosphamide for Graft Vs. Host Disease Prophylaxis In Older-Aged or Medically Frail Patients with Advanced Hematological Malignancies. Blood (ASH Annual Meeting Abstracts) 116 (#2341), 12/2010.
  • Krishman A, Pasquini MC, Ewell M, Stadtmauer EA, Alyea III EP, Antin JH, Comenzo RL, Goodman S, Parameswaran H, Negrin R, Qazilbash MH, Rowley SD, Sahebi F, Somlo G, Vesole DH, Vogl DT, Weisdorf DJ, Geller N, Horowitz MM, Giralt S, Maloney DG. Tandem Autologous Hematopoietic Stem Cell Transplants (AuHCT) with or without Maintenance Therapy (auto-auto) Versus Single AuHCT Followed by HLA Matched Sibling Non- Myeloablative Allogeneic HCT (auto-allo) for Patients with Standard Risk (SR) Multiple Myeloma (MM): Results From the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial. Blood (ASH Annual Meeting Abstracts). 116 (#41), 12/2010.
  • Stadtmauer EA, Krishnan A, Pasquini MC, Ewell M, Alyea III EP, Antin JH, Castro-Malaspina H, Kissim AA, Negrin R, Qazilbash MH, Rizzo JD, Rowley SD, Sahebi F, Somlo G, Vesole DH, Vogl DT, Weisdorf DJ, Geller N, Horowitz MM, Maloney DG, Giralt S. Tandem Autologous Stem Cell Transplants (auto-auto) with or without Maintenance Therapy Versus Single Autologous Transplant Followed by HLA-Matched Sibling Non- Myeloablative Allogeneic Stem Cell Transplant (auto-allo) for Patients (pts) with High Risk (HR) Multiple Myeloma (MM): Results From the Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) 0102 Trial. Blood (ASH Annual Meeting Abstracts). 116 (#526), 12/2010.
  • Sharma MR, Ravandi F, Chiattone A, Kebriaei P, Popat U, Giralt S, Bashir Q, Qazilbash MH, Nieto Y, Yuen CH-L, Parmar S, Kantarjian HM, Cortes J, Kadia T, Borthakur G, Champlin RE, de Lima M. Treatment of FLT3-ITD Positive AML Relapsing After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) with Sorafenib. Blood (ASH Annual Meeting Abstracts). 116 (#3471), 12/2010.
  • Syed Kazmi, MD1*, Gary Lu, MD2*, Nina Shah, MD3*, Qaiser Bashir, MD3*, Simrit Parmar, M.D.4, Robert Z. Orlowski, MD, PhD5, Jatin J Shah, MD6, Chitra M Hosing, MD4, Uday Popat, M.D.3, Yvonne T Dinh3*, Sofia Qureshi3*, Gabriela Rondon, MD7*, Sergio Giralt, MD8*, Richard Champlin, MD3 and Muzaffar H. Qazilbash, MD9. A Comparative Study of the Outcome of High-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation in Patients with High-Risk or Standard-Risk Myeloma Treated Concurrently. ASH Annual Meeting 2011 Abstract, 1/2011.
  • Muzaffar Qazilbash, MD1,2, Peter F Thall, PhD3*, Ping Liu4*, Robert Z. Orlowski, MD, PhD5, Qaiser Bashir, MD6*, Nina Shah, MD6*, Partow Kebriaei, MD6, Simrit Parmar, MD7, Roy Jones, MD, PhD8*, Chitra M Hosing, MD6, Uday R Popat, MD6, Yvonne T Dinh2*, Gabriela Rondon, MD2*, Jatin J Shah, MD9, Marcos De Lima, MD6, Richard Champlin, MD6 and Sergio Giralt, MD10. A Randomized Phase II Trial of Fludarabine/Melphalan 140 Vs Fludarabine/ Melphalan 100 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma. ASH Annual Meeting 2011 Abstract, 1/2011.
  • Pemmaraju N, Ravandi F, Rondon G, Giralt S, Chen J, Pierce S, Champlin RE, de Lima M, Qazilbash M. Analysis of outcomes in patients (pts) with relapsed/refactory acute promyelocytic leukemia (APL) treated with and without high-dose chemotherapy and heamtopoietic stem cell transplantation (HCT). ASCO Meeting Abstracts. 2011 Vol 29(No 15_suppl):(May 20 Supplement), 2011 (#6608), 5/2011.
  • Beitinjaneh A, Saliba R, Okoroji G, Alousi AM, Popat UR, Korbling M, Anderlini P, Qazilbash M, Kebriaei P, Hosing C, Champlin RE, Khouri IF. Autologous stem cell transplantation (ASCT) as upfront or salvage therapy for noncutaneous T-cell lymphoma (TCL): The University of Texas M. D. Anderson Cancer Center (MDACC) experience. ASCO Meeting Abstracts. 2011 29(15):May 20 Supplement (#6565), 5/2011.
  • Khouri IF, Saliba R, Alousi AM, Popat UR, Anderlini P, Kebriaei P, Qazilbash M, Champlin RE, Bassett RL. Bendamustine in combination with fludarabine and rituximab: A novel nonmyeloablative conditioning for allogeneic stem cell transplantation (AST) in patients with lymphoid malignancies. ASCO Meeting Abstracts. 2011 29(15):May 20 Supplement), 2011 (#e18511), 5/2011.
  • Uday Popat, M.D.1, Borje S Andersson, MD, PhD2*, Roland Bassett3*, Stefan Ciurea2, Gabriela Rondon, MD2*, Amin M Alousi, MD1*, Paolo Anderlini, MD1, Chitra Hosing, MD2*, Roy Jones, MD, PhD2*, Partow Kebriaei, MD1, Yago Nieto, MD, PhD2, Issa Khouri, MD2, Elizabeth J Shpall, MD1, Srdan Verstovsek, MD, PhD4, Muzaffar Qazilbash, MD2, Marcos J de Lima, MD1* and Richard Champlin, MD5. Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: PK Guided IV Busulfan Dose Intensity Results in Improved Event Free Survival. ASH Annual Meeting 2011 Abstract, 12/2011.
  • Amer Beitinjaneh, MD, MPH1, Rima M. Saliba, PhD2*, Grace-Julia Okoroji3*, Martin Korbling, MD2*, Amin M Alousi, MD2*, Uday Popat, MD4, Paolo Anderlini, MD5, Qaiser Bashir, MD6*, Borje S Andersson, MD, PhD5*, Partow Kebriaei, MD7, Chitra M Hosing, MD6, Muzaffar Qazilbash, MD1, Michelle A. Fanale, MD8, Barbara Pro, MD9*, Richard Champlin, MD6 and Issa Khouri, MD10. Autologous and Allogeneic Stem Cell Transplantation for T-Cell Lymphoma: The M.D. Anderson Cancer Center Experience. ASH Annual Meeting 2011 Abstract, 12/2011.
  • Vamsi Kota, MBBS1, Rima M. Saliba, PhD2*, Ulas D. Bayraktar, MD2*, Amer Beitinjaneh, MD3*, Julianne J Chen4*, Simrit Parmar, M.D.2,4, Sergio A Giralt, MD5, Gabriela Rondon, MD6,7*, Stefan O Ciurea, MD2, Partow Kebriaei, MD2,8, Muzaffar H Qazilbash, MD9, Borje S Andersson, MD, PhD4,7*, Richard Champlin, MD2,4,10 and Marcos De Lima, MD2. Chromosome 7 Abnormalities in Allogeneic Transplantation for AML and MDS. ASH Annual Meeting 2011 Abstract, 12/2011.
  • Yago Nieto, MD, PhD1, Peter F Thall, PhD2*, Borje S Andersson, MD, PhD3*, Uday R Popat, MD1, Paolo Anderlini, MD3, Benigno C. Valdez, PhD1, Elizabeth J Shpall, MD3, Muzaffar Qazilbash, MD3, Amin M Alousi, MD1*, Christina Chancoco1*, Chitra M Hosing, MD1, Partow Kebriaei, MD1, Qaiser Bashir, MD1*, Nina Shah, MD1*, Issa Khouri, MD4, Stefan O Ciurea, MD1, Becky McMullin, RN1*, Gabriela Rondon, MD3*, Richard Champlin, MD1 and Roy Jones, MD, PhD. High-Dose Infusional Gemcitabine (Gem) Combined with Busulfan (Bu) and Melphalan (Mel) (GemBuMel) with Autologous Stem-Cell Transplant (ASCT) in Patients with Refractory Lymphoid Malignancies. ASH Annual meeting 2011 Abstract, 12/2011.
  • Parameswaran Hari, MBBS, MD, MRCP1, Marcelo C Pasquini, MD, MS1, Brent R. Logan, PhD1*, Edward A. Stadtmauer, MD2, Amrita Krishnan, MD3, Alan Howard, PhD4*, Sairah Alvi, PhD5, Stephen Harding6*, Shelly L Carter, ScD7*, Vincent Rajkumar, MD8*, Edwin P Alyea III, MD9, Muzaffar Qazilbash, MD10, Ginna G. Laport, MD11, David G. Maloney, MD, PhD12, Sergio Giralt, MD13 and David H. Vesole, MD, PhD14. Immunoglobulin Free Light Chain (FLC) and Heavy Chain/Light Chain (HLC) Assays – Comparison with Electrophoretic Responses in Multiple Myeloma (MM). ASH Annual Meeting 2011 Abstract, 12/2011.
  • Sairah Ahmed, MD1, Heather Lin, PhD1*, Veera Baladandayuthapani, PhD1*, Mubeen A Khan1*, Gary Lu, MD2*, Gabriela Rondon, MD3, Sofia Qureshi1*, Yvonne T Dinh1*, Qaiser Bashir, MD1*, Nina Shah, MD1*, Simrit Parmar, M.D.4, Chitra M Hosing, MD5, Uday Popat, M.D.1, Sergio A Giralt, MD6, Robert Z. Orlowski, MD, PhD7, Jatin J Shah, MD8, Richard Champlin, MD1 and Muzaffar H. Qazilbash, MD1. Impact of Non High-Risk Chromosomal Abnormalities on the Outcome of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. ASH Annual Meeting 2011 Abstract, 12/2011.
  • Stefan O Ciurea, MD1, Rima M. Saliba, PhD1*, Ulas D. Bayraktar, MD1*, Susan Xie1*, Gabriela Rondon, MD2*, Simrit Parmar, M.D.1, Partow Kebriaei, MD1, Nivia Montes, PA1*, Manish Sharma, MD1*, Marina Konopleva, M.D., Ph.D.3, Yago Nieto, MD, PhD1, Muzaffar H. Qazilbash, MD1, Amin M Alousi, MD1*, Borje S Andersson, MD, PhD2*, Chitra M Hosing, MD1, Elizabeth J Shpall, MD2, Issa F. Khouri, MD1, Marcos de Lima, MD1* and Richard Champlin, MD1. Improved Early Outcomes with T-Cell Replete (TCR) Compared with T-Cell Depleted (TCD) Haploidentical Stem Cell Transplantation (HaploSCT). ASH Annual Meeting 2011 Abstract, 12/2011.
  • Nina Shah, MD1*, Qaiser Bashir, MD1*, Simrit Parmar, M.D.2, Yvonne T Dinh1*, Sofia Qureshi1*, Gabriela Rondon, MD1*, Uday R Popat, MD2, Yago Nieto, MD, PhD2, Roy Jones, MD, PhD3*, Richard Champlin, MD2 and Muzaffar H. Qazilbash, MD4. Increased Bone Marrow Plasma Cell Infiltration Pre-Transplant Is Associated with Worse Outcomes in Patients Undergoing High Dose Chemotherapy and Autologous Stem Cell Transplantation for Multiple Myeloma. ASH Annual Meeting 2011 Abstract, 12/2011.
  • Issa F Khouri, MD1, Rima M Saliba, Ph.D.2*, Rosamar Valverde3*, Barry I Samuels, MD4*, Martin Korbling, MD2*, Amin M Alousi, MD2*, Paolo Anderlini, MD1, Qaiser Bashir, MD1*, Marcos De Lima, MD5, Chitra Hosing, MD6, Partow Kebriaei, MD7, Yago Nieto, MD, PhD2, Uday R Popat, MD2, Muzaffar Qazilbash, MD1, Sattva Neelapu, MD8, Nathan H. Fowler, MD6, Felipe Samaniego, MD8, Luhua Wang, MD9, Richard Champlin, MD1 and Homer A Macapinlac, MD10. Nonmyeloablative Allogeneic Stem Cell Transplantation with/ or without 90yttrium Ibritumomab Tiuxetan (90YIT) Is Curative for Relapsed Follicular Lymphoma: Median 9 Year Follow-up Results. ASH Annual Meeting 2011 Abstract, 12/2011.
  • Issa F Khouri, MD1, Rima M Saliba, PhD1*, Martin Korbling, MD2*, Amin M Alousi, MD2*, Uday R Popat, MD2, Paolo Anderlini, MD3, Stefan O Ciurea, MD2, Partow Kebriaei, MD4, Muzaffar H. Qazilbash, MD5*, Richard Champlin, MD2 and Roland L Bassett Jr. Nonmyeoablative Allogeneic Conditioning with Bendamustine in Combination with Fludarabine and Rituximab for Lymphoid Malignancies: Immunosuppression without Myelosuppression and without Acute Gvhd. ASH Annual Meeting 2011 Abstract, 12/2011.
  • Rima M Saliba, Ph.D.1*, Alexandre Chiattone, MD2*, Alejandro Majlis, MD3, Viviane C. Chiattone, RN4*, Gabriela Rondon, MD5*, Araci M. Sakashita, MD6*, Nelson Hamerschlak, MD6, Jose Mauro Kutner, MD, PhD6, Elizabeth J Shpall, MD1, Paolo Anderlini, MD7, Issa Khouri, MD8, Muzaffar H Qazilbash, MD9, Uday Popat, M.D.1, Richard Champlin, MD1, Chitra M Hosing, MD1 and Marcos De Lima, MD1. Predictors of Stem Cell Yield Via Apheresis in Patients Undergoing Stem Cell Mobilization. ASH Annual Meeting 2011 Abstract, 12/2011.
  • Yi Zhou, MD, PhD1*, Jeffrey L. Jorgensen, MD, PhD2*, Rima M Saliba, PhD3*, Sa A. Wang, MD4*, Gabriela Rondon, MD5*, Celina Ledesma, B.S.6*, Borje S Andersson, MD, PhD6*, Marcos J de Lima, MD7*, Elizabeth J Shpall, MD7, Uday Popat, M.D.8, Stefan O Ciurea, MD7, Amin M Alousi, MD7*, Muzaffar Qazilbash, MD8, Chitra M Hosing, MD9, L. Jeffrey Medeiros, MD4, Richard Champlin, MD10 and Partow Kebriaei, MD. Pre-Transplant Minimal Residual Disease Detected by Multiparameter Flow Cytometric Analysis Predicts for Disease Relapse in Adult Patients with Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Stem Cell transplantation. ASH Annual Meeting 2011 Abstract, 12/2011.
  • Shatha Farhan, MD1*, Heather Lin, PhD1*, Veerabhadran Baladandayuthapani1*, Nina Shah, MD2*, Qaiser Bashir, MD2*, Chitra M Hosing, MD1, Uday Popat, M.D.1, Simrit Parmar, M.D.1, Yvonne T Dinh2*, Sofia Qureshi2*, Gabriela Rondon, MD1*, Sergio Giralt, MD1*, Richard Champlin, MD1 and Muzaffar H. Qazilbash, MD1. Response Before Autologous Hematopoietic Stem Cell Transplantation Is An Important Predictor of Outcome in Multiple Myeloma. ASH Annual Meeting 2011 Abstract, 12/2011.
  • Sairah Ahmed, MD1, Yvonne T Dinh1*, Sofia Qureshi1*, Gabriela Rondon, MD1*, Qaiser Bashir, MD1*, Simrit Parmar, M.D.2, Tiffany Avery, MD, MPH3*, Robert Z. Orlowski, MD, PhD4, Richard Champlin, MD2, Muzaffar Qazilbash, MD1 and Nina Shah, MD1. Survival Disparities Between African-American and Caucasian Patients Treated with Autologous Stem Cell Transplantation for Multiple Myeloma Are Eliminated in the Era of Novel Therapeutics. ASH Annual Meeting 2011 Abstract, 12/2011.
  • Hosing C, Saliba R, Singh L, Popat U, Qazilbash M, Anderlini P, Nieto Y, Alousi A, Frazier E, Dabaja E, Champlin R, Duvic M. Total Skin Electron Beam radiation therapy and allogeneic haematopoietic stem cell transplantation in advanced mycosis fungoides and Sézary syndrome. Nature/2012 EBMT Abstract Book 47(Supplement 1):S85 (#O368), 4/2012.
  • Hans C. Lee, MD1, C. Cameron Yin, MD, PhD2, Muzaffar H. Qazilbash, MD3, Iris Wang, MD2*, Victoria Lu2* and Gary Lu, MD2*. Acquired Therapy-Related Cytogenetic Clones in Patients Treated for Multiple Myeloma. ASH Annual Meeting 2012 Abstracts, 12/2012.
  • Zartash Gul, MD1*, Qaiser Bashir, MD2*, Yago Nieto, M.D., Ph.D.2, Nazeer Sherwani3*, Simrit Parmar, M.D.4, Nina Shah, MD4*, Yvonne T Dinh4*, Chitra M. Hosing, M.D.2,4, Uday R. Popat, M.D.2, Partow Kebriaei, M.D.2, Elizabeth J Shpall, MD2, Sergio A Giralt, MD5, Richard E. Champlin6 and Muzaffar H. Qazilbash, MD2. Cardiac Toxicity After High-Dose Melphlan and Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. ASH Annual Meeting 2012 Abstracts, 12/2012.
  • Amin M. Alousi, M.D.1, Rima M Saliba, PhD1*, Julianne Chen1*, Borje S Andersson, MD, PhD1*, Issa Khouri, MD2, Muzaffar H. Qazilbash, MD1, Uday R. Popat, M.D.1, Chitra M. Hosing, M.D.1, Stefan O. Ciurea1, Elizabeth J Shpall, MD1, Roy B. Jones, MD, Ph.D.1*, Partow Kebriaei, M.D.1, Yago Nieto, M.D., Ph.D.1, Paolo Anderlini, MD1, Marcos DeLima, MD3*, Gabriela Rondon4 and Richard E. Champlin1. A Matched Controlled Analysis of Post-Transplant Cyclophosphamide (CY) Versus Tacrolimus and Mini-Dose Methotrexate in Matched Sibling and Unrelated Donor Transplant Recipients Receiving Reduced-Intensity Conditioning: Post-Transplant CY Is Associated with Higher Rates of Acute Gvhd. ASH Annual Meeting 2012 Abstracts, 12/2012.
  • Zartash Gul, MD1, Hasan Khan2*, Qaiser Bashir, MD3, Nina Shah, MD4*, Simrit Parmar, M.D.5, Yvonne T Dinh6*, Chitra M. Hosing, M.D.3, Uday R. Popat, M.D.3, Partow Kebriaei, M.D.3, Paolo Anderlini, MD3, Elizabeth J Shpall, MD3, Sergio Giralt, MD7, Richard E. Champlin3 and Muzaffar H. Qazilbash, MD8. EBMT Risk Score for Pre Transplant Risk Assessment in Patients with Multiple Myeloma. ASH Annual Meeting 2012 Abstracts, 12/2012.
  • Dilshad Khan, MBBS1*, Krina Patel, MD2*, Sheeba K. Thomas, MD3, Donna M. Weber, M.D.3, Kay B Delasalle, B.S.4*, Chitra M. Hosing, M.D.5, Uday R. Popat, M.D.1, Qaiser Bashir, MD1*, Nina Shah, MD1*, Simrit Parmar, M.D.6, Richard E. Champlin5 and Muzaffar Qazilbash, M.D.5. Feasibility of Hematopoietic Stem Cell Collection and Cryopreservation in Waldenstrom’s Macroglobulinemia. ASH Annual Meeting 2012 Abstracts, 12/2012.
  • Jatin J. Shah, M.D.1, Robert Z. Orlowski, M.D., Ph.D.2, Sheeba K. Thomas, MD1, Raymond Alexanian, M.D.2, Michael Wang, M.D.3, Muzaffar H. Qazilbash, MD4, Uday R. Popat, M.D.5, Simrit Parmar, M.D.6, Nina Shah, MD7*, Qaiser Bashir7, Richard E. Champlin8 and Donna M. Weber, M.D.1. Final Results of a Phase I/II Trial of the Combination of Concurrent Lenalidomide, Thalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Myeloma. ASH Annual Meeting 2012 Abstracts, 12/2012.
  • Jatin J. Shah, M.D.1, Donna M. Weber, M.D.1, Sheeba K. Thomas, MD1, Raymond Alexanian, M.D.2, Michael Wang, M.D.3, Muzaffar H. Qazilbash, MD4, Simrit Parmar, M.D.5, Nina Shah, MD6*, Qaiser Bashir, MD7, Uday R. Popat, M.D.8, Brandi Hilder9* and Robert Z. Orlowski, M.D., Ph.D.2. hase 1 Study of the Novel Kinesin Spindle Protein Inhibitor ARRY-520 + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma. ASH Annual Meeting 2012 Abstracts, 12/2012.
  • Simrit Parmar, M.D.1, Joshua Howell, PharmD2*, Michael Wang, M.D.3, Mubeen A Khan4,5*, Qaiser Bashir, MD2,4*, Jatin J. Shah, M.D.6, Nina Shah, MD2*, Uday R. Popat, M.D.7, Sergio A Giralt, MD8, Robert Z. Orlowski, M.D., Ph.D.9 and Muzaffar Qazilbash, M.D.4. High Dose Therapy Improves Survival in Systemic Light Chain Amyloidosis: 14 Year Follow up. ASH Annual Meeting 2012 Abstracts, 12/2012.
  • Amir Hamdi, M.D.*, LM Poon, M.D.*, Rima M. Saliba, Ph.D.*, Gabriela Rondon, M.D., Celina Ledesma*, Muzaffar Qazilbash, M.D., Chitra M. Hosing, M.D., Roy B. Jones, MD, Ph.D.*, Uday R. Popat, M.D., Yago Nieto, M.D., Ph.D., Amin M. Alousi, M.D., Stefan O. Ciurea, Elizabeth J. Shpall, M.D., Richard E. Champlin and Partow Kebriaei, M.D. Outcomes of Adults with Acute Lymphoblastic Leukemia (ALL) Following Relapse After First Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). ASH Annual Meeting 2012 Abstracts, 12/2012.
  • atin J. Shah, M.D.1, Sheeba K. Thomas, MD1, Donna M. Weber, M.D.1, Michael Wang, M.D.2, Raymond Alexanian, M.D.3, Muzaffar H. Qazilbash, MD4, Qaiser Bashir, MD5, Simrit Parmar, M.D.6, Nina Shah, MD7*, Uday R. Popat, M.D.5 and Robert Z. Orlowski, M.D., Ph.D.3. Phase 1/1b Study of the Efficacy and Safety of the Combination of Panobinostat + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma. ASH Annual Meeting 2012 Abstracts, 12/2012.
  • Krina Patel, MD1*, Robert Z. Orlowski, M.D., Ph.D.2, Nina Shah, MD3*, Qaiser Bashir3, Simrit Parmar, M.D.3, Yvonne T Dinh3*, Gabriela Rondon, MD3*, Sergio A Giralt, MD4, Richard E. Champlin3 and Muzaffar Qazilbash, M.D.3. Role of Serum Lactate Dehydrogenase (LDH) As a Prognostic Marker for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. ASH Annual Meeting 2012 Abstracts, 12/2012.
  • airah Ahmed, MD1, Rima M Saliba, Ph.D1*, Marcos De Lima, MD1, Gabriela Rondon, MD1, Partow Kebriaei, MD1, Tobi DeAnn Fisher, MPAS1*, Elias Jabbour, MD2, Julianne Chen1*, Hagop Kantarjian, MD2, Paolo Anderlini, MD1, Amin M Alousi, MD1, Chitra M Hosing, MD1, Borje Andersson, MD, PhD1, Roy B. Jones, MD, Ph.D.1*, Muzaffar H. Qazilbash, MD1, Elizabeth J. Shpall, MD1, Sergio Giralt, MD3 and Richard E Champlin, MD1. Sequential Treatment After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia. ASH Annual Meeting 2012 Abstracts, 12/2012.
  • Uday R. Popat, Roland Bassett, Julianne Chen, Amin Majid Alousi, Paolo Anderlini, Stefan O. Ciurea, Chitra Hosing, Roy B. Jones, Partow Kebriaei, Issa F. Khouri, Sergej Konoplev, Marcos De Lima, Yago Nieto, Betul Oran, Muzaffar H. Qazilbash, Gabriela Rondon, Elizabeth J. Shpall, Srdan Verstovsek, Borje Andersson and Richard E. Champlin. Allogeneic transplantation for myelofibrosis: Benefit of dose intensity. ournal of Clinical Oncology, 2013 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Volume 31(No 15):7011, 5/2013.
  • Antonio Martin Jimenez, Marcos De Lima, Uday R. Popat, Gautam Borthakur, Lynne Abruzzo, Borje Andersson, Guillermo Garcia-Manero, Elias Jabbour, Julianne Chen, Qaiser Bashir, Stefan O. Ciurea, Partow Kebriaei, Sairah Ahmed, Issa F. Khouri, Piyanuch Kongtim, Muzaffar H. Qazilbash, Gabriela Rondon, Elizabeth J. Shpall, Richard E. Champlin, and Betul Oran. Impact of monosomal karyotype and FLT3 status on post-transplant relapse in acute myeloid leukemia (AML). Journal of Clinical Oncology- ASCO Annual Meeting Volume 31(No 15):7010, 5/2013.
  • Naveen Pemmaraju, MD, Dhaval Shah, MD, Hagop M Kantarjian, MD, Verena Wagner, Robert Z. Orlowski, M.D., Ph.D., Guillermo Garcia-Manero, MD, Farhad Ravandi, MD, Sherry Pierce, Koichi Takahashi, MD, Naval G. Daver, MD, Aziz Nazha, MD, Srdan Verstovsek, MD, PhD, Elias J. Jabbour, MD, Marcos J de Lima, MD, Richard E Champlin, MD, Jorge E. Cortes, MD and Muzaffar H. Qazilbash, MD. Characteristics and Outcomes Of Patients (pts) With Multiple Myeloma (MM) Who Develop Therapy (t)-Related Myelodysplastic Syndrome (MDS), t-Chronic Myelomonocytic Leukemia (CMML), Or t-Acute Myeloid Leukemia (AML). ASH 2013 Abstracts, 2013.
  • Sai Ravi Pingali, MD, Rima M Saliba, PhD, Veronica R. Smith, APN, Farzaneh Maadani, Kehinde U.A. Adekola, MBBS, Uday R Popat, MD, Muzaffar H. Qazilbash, MD, Qaiser Bashir, MD, Issa Khouri, MD, Partow Kebriaei, MD, Stefan O. Ciurea, MD, Paolo Anderlini, MD, Nina Shah, MD, Yago Nieto, MD, PhD, Richard E Champlin, MD and Chitra M. Hosing, MD. Number Of Apheresis Days To Reach Target Stem Cell Dose May Be a Predictor Of Secondary Myelodysplastic Syndrome and Acute Myelogenous Leukemia. ASH 2013 Abstracts, 2013.
  • Maliha Nusrat, MD, Syed M. Kazmi, MD, Amanda Megan Cornelison, MS, PA-C, Partow Kebriaei, MD, Yago Nieto, MD, PhD, Betul Oran, MD, Robert Z. Orlowski, M.D., Ph.D., Simrit Parmar, MD, Uday R Popat, MD, Jatin J. Shah, M.D., Nina Shah, MD, Richard E Champlin, MD, Muzaffar H. Qazilbash, MD and Qaiser Bashir, MD. Outcomes Among High Risk and Standard Risk Multiple Myeloma Patients Treated With High Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation. ASH 2013 Abstracts, 2013.
  • Armin Ghobadi, MD, Amir Hamdi, MD, Piyanuch Kongtim, MD, Denai Milton, Amin Alousi, MD, Paolo Anderlini, MD, Stefan O. Ciurea, MD, Betul Oran, MD, Issa Khouri, MD, Simrit Parmar, MD, Muzaffar H. Qazilbash, MD, Partow Kebriaei, MD, Uday R Popat, MD, Katy Rezvani, MD, PhD, Roy F Chemaly, MD, MPH, Elizabeth J Shpall, MD, Richard E Champlin, MD and Qaiser Bashir, MD. The Effect Of CMV Reactivation On Relapse and Survival In Patients With AML and MDS After Allogeneic Stem Cell Transplant (allo-HCT). ASH 2013 Abstracts, 2013.
  • Antonio Di Stasi, MD, LM Poon, M.D., Roberto Ferro, MD, Denai Milton, Gabriela Rondon, MD, Sa A. Wang, MD, Amir Hamdi, MD, Muzaffar H. Qazilbash, MD, Sairah Ahmed, MD, Issa Khouri, MD, Betul Oran, MD, Chitra M. Hosing, MD, Partow Kebriaei, MD, Amin Alousi, MD, Uday R Popat, MD, Elizabeth J Shpall, MD, Dean A. Lee, MD, PhD, Katy Rezvani, MD, PhD, Richard E Champlin, MD and Stefan O. Ciurea, MD. Transplant Outcomes For Patients With AML/MDS Using Melphalan-Based Conditioning. ASH 2013 Abstracts, 2013.
  • Yago Nieto, MD, PhD, Peter F Thall, PhD, Benigno C. Valdez, PhD, Chitra M Hosing, MD, Sairah Ahmed, MD, Roy B Jones, PhD MD, Nina Shah, MD, Paolo Anderlini, MD, Muzaffar H. Qazilbash, MD, Uday R Popat, MD, Qaiser Bashir, MD, Elizabeth J Shpall, MD, Amin Alousi, MD, Partow Kebriaei, MD, Patricia Fox, MS, Rolland Bassett, MS, Christina Chancoco, Yasuhiro Oki, MD, Michelle A. Fanale, MD, Nathan Fowler, MD, Frederick Hagemeister, MD, Jorge E Romaguera, MD, Richard E Champlin, MD and Borje S. Andersson, MD, PhD. Vorinostat (SAHA) Combined With High-Dose Gemcitabine/Busulfan/Melphalan (SAHA/Gem/Bu/Mel) With Autologous Stem-Cell Transplant (ASCT) In Patients With Refractory Lymphomas. ASH 2013 Abstracts, 2013.
  • Sheeba K. Thomas, M.D., Tamara M Haygood, M.D., Muzaffar H. Qazilbash, MD, A. Georgina Melendez, M.D., Roxana Galvis, Kay B Delasalle, B.S., Lei Feng, M.S., Tiffany A. Richards, M.S., Felipe Samaniego, M.D., M.P.H, Luhua Wang, M.D., Jatin J. Shah, M.D., Robert Z. Orlowski, M.D., Ph.D. and Donna M. Weber, M.D. A Phase II Trial Of Bortezomib-Rituximab Followed By Autologous Stem Cell Harvest (SCH) and Cladribine-Cyclophosphamide-Rituximab (2CdA-Cy-Rit) Consolidation As Primary Therapy Of Waldenström's Macroglobulinemia (WM). ASH 2013 Abstracts, 2013.
  • Piyanuch Kongtim, MD, Muzaffar H. Qazilbash, MD, Jatin J. Shah, M.D., Robert Z. Orlowski, M.D., Ph.D., Amir Hamdi, MD, Nina Shah, MD, Qaiser Bashir, MD, Michael Wang, MD, Richard E Champlin, MD and Simrit Parmar, MD. Autologous Stem Cell Transplantation Improves Survival For High Risk Cardiac Amyloidosis. ASh 2013 Abstracts, 2013.
  • Kehinde U.A. Adekola, MD, Qaiser Bashir, MD, Nina Shah, MD, Sai Ravi Pingali, MD, Simrit Parmar, MD, Uday R Popat, MD, Chitra M. Hosing, MD, Richard E Champlin, MD and Muzaffar H. Qazilbash, MD. Characteristics Of Multiple Myeloma Patients With 6-Year Or Longer Progression-Free Survival After a Single Autologous Transplant. ASH 2013 Abstracts, 2013.
  • Betul Oran, MD, Michelle Poon, Julianne Chen, Gabriela Rondon, MD, Sairah Ahmed, MD, Borje S. Andersson, MD, PhD, Qaiser Bashir, MD, Stefan O. Ciurea, MD, Chitra M. Hosing, MD, Simrit Parmar, MD, Muzaffar H. Qazilbash, MD, Uday R Popat, MD, Yago Nieto, MD, PhD, Amin Alousi, MD, Roy B Jones, PhD MD, Katy Rezvani, MD, PhD, Marcos de Lima, MD, Elizabeth J Shpall, MD, Richard E Champlin, MD and Partow Kebriaei, MD. Comparable Outcomes After Sibling and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantations (HCT) In Adult Acute Lymphoblatic Leukemia (ALL) With First Complete Remission (CR). ASH 2013 Abstracts, 2013.
  • Uday R Popat, MD, Betul Oran, MD, Chitra M. Hosing, MD, Partow Kebriaei, MD, Katy Rezvani, MD, PhD, Simrit Parmar, MD, Nina Shah, MD, Catherine M. Bollard, MBChB, MD, Jeffrey J. Molldrem, MD, Yago Nieto, MD, PhD, Borje S. Andersson, MD, PhD, Amin Alousi, MD, Roy B. Jones, MD, PhD, Laurence J N Cooper, MD, PhD, Muzaffar H. Qazilbash, MD, Qaiser Bashir, MD, Sairah Ahmed, MD, Doyle Bosque, ADN, Julianne Chen, Jessica McCarty, Gabriela Rondon, MD, Mark Munsell, Ian K. McNiece, PhD, Indreshpal Kaur, PhD, Eric Yvon, PhD, Katherine Annandale, Sarah Olchesky, Marcos J de Lima, MD, Richard E  Champlin, MD, Leonard Miller, PhD, Linda Paradiso, DVM.MBA, Lynnet Koh, MS, MBA, Patrick A. Zweidler-McKay, MD/PhD and Elizabeth J Shpall, MD. Ex Vivo Fucosylation Of Cord Blood Accelerates Neutrophil and Platelet Engraftment. ASH 20103 Abstracts, 2013.
  • Yago Nieto, MD, PhD, Nina Shah, MD, Uday R Popat, MD, Roy B Jones, PhD MD, Qaiser Bashir, MD, Rolland Bassett, MS, Benigno C. Valdez, PhD, Borje S Andersson, MD, PhD, Simrit Parmar, MD, Robert Z. Orlowski, M.D., Ph.D, Jatin J. Shah, M.D., Sheeba K. Thomas, M.D., Michael Wang, M.D., Richard E Champlin, MD and Muzaffar Qazilbash, M.D. High-Dose Gemcitabine Combined With Busulfan and Melphalan (Gem/Bu/Mel) With Autologous Stem-Cell Transplant (ASCT) In Refractory and Relapsed Myeloma. ASH 2013 Abstracts, 2013.
  • Nina Shah, MD, Loretta A Williams, PhD, RN, Audrey Worthing, RN, Qiuling Shi, PhD, Xin Shelley Wang, MD, MPH, Valen Johnson, PhD, Tito R Mendoza, PhD, Muzaffar H. Qazilbash, MD, Richard E Champlin, MD, Sergio A Giralt, MD and Charles S. Cleeland, PhD. Higher Stem Cell Dose Infusion As Rescue After Intensive Chemotherapy Does Not Improve Symptom Burden In Older Patients With Multiple Myeloma and Amyloidosis. ASh 2013 Abstracts, 2013.
  • Suzanne C Gettys, PharmD, Alison M Gulbis, PharmD, BCOP, Kaci Wilhelm, PharmD, BCOP, Yvonne T Dinh, Gabriela Rondon, MD and Muzaffar H. Qazilbash, MD. Modified-CVAD Or Modified-Cbad Compared To High Dose Cyclophosphamide For Peripheral Blood Stem Cell Mobilization In Patients With Multiple Myeloma. ASH 2013 Abstracts, 2013.
  • Jatin J. Shah, M.D., Veera Baladandayuthapani, PhD, Donna M. Weber, M.D., Sheeba K. Thomas, M.D., Raymond Alexanian, M.D., Michael Wang, MD, Muzaffar H. Qazilbash, MD, Richard E Champlin, MD, Nina Shah, MD, Qaiser Bashir, MD, Uday R Popat, MD, Yago Nieto, M.D., Ph.D., Sairah Ahmed, MD, Simrit Parmar, MD and Robert Z. Orlowski, M.D., Ph.D. Phase II Study Of The Combination Of MLN 9708 With Lenalidomide As Maintenance Therapy Post Autologous Stem Cell Transplant In Patients With Multiple Myeloma. ASH 2013 Abstracts, 2013.
  • Krina Patel, MD, Lei Feng, M.S., Yasuhiro Oki, MD, Muzaffar Qazilbash, M.D.4, Tariq Muzzafar, MBBS, Donna M. Weber, M.D., Nathan Fowler, MD, Uday R Popat, MD, Sheeba K. Thomas, M.D., Michelle A. Fanale, MD, Yago Nieto, MD, PhD, Nina Shah, MD, Qaiser Bashir, MD, Fredrick B. Hagemeister, MD, Robert Z. Orlowski, M.D., Ph.D. and Jatin J. Shah, M.D. Plasmablastic Lymphoma: 28 Patient Single Institution Experience, 2013.

Book Chapters

  • Qazilbash M. Chronic Leukemias. In: Bethesda Handbook of Clinical Oncology. Lippincott Williams & Wilkins, 2004.
  • Qazilbash M. Chronic Myeloid Leukemia. In: Bethesda Handbook of Clinical Oncology. Lippincott Williams & Wilkins, 2004.
  • Qazilbash MH, Cortes JE. Myeloid Leukemia. In: Bethesda Handbook of Clinical Oncology, Second. Ed(s) Abraham J, Gulley JL, Allegra C. Lippincott Williams & Wilkins: Baltimore, 331, 2005.
  • Qazilbash MH, Giralt SA. Hematopoietic Cell Transplantation for Multiple Myeloma. In: Thomas' Hematopoietic Cell Transplantation, 4. Ed(s) Applebaum FR, Forman SJ, Negrin RS, Blume KG. Wiley Blackwell, 845-59, 2009.
  • Saraih Ahmed, Muzaffar Qazilbash. Chronic Myeloid Leukemia. In: The Bethesda Handbook of Clinical Oncology, 4th Edition. Ed(s) James Abraham, James l. Gulley, Carmen J. Allegra, 328-334, 2014.
  • Qazilbash MH. Peptide Vaccines for AML. In: Immunotherapy and Gene Therapy. Springer Science. In Press. Maxwell E. Phelps Award for Scholarship, University of Connecticut, 1992
  • Trainee Investigator Award, American Society for Clinical Investigation, 1997
  • Junior Faculty Award, Cure for Lymphoma Foundation and Lymphoma Research Foundation of American, Hawaii, 2001
  • Excellent Review Award, CRC/PBHSRC, Office of Protocol Research, UT- MD Anderson Cancer Center, 2004
  • Recipient of ASBMT Travel Grant for Tandem, ASBMT, 2006
  • Maxwell E. Phelps Award for Scholarship, University of Connecticut, 1992
  • Trainee Investigator Award, American Society for Clinical Investigation, 1997
  • Junior Faculty Award, Cure for Lymphoma Foundation and Lymphoma Research Foundation of American, Hawaii, 2001
  • Excellent Review Award, CRC/PBHSRC, Office of Protocol Research, UT- MD Anderson Cancer Center, 2004
  • Recipient of ASBMT Travel Grant for Tandem, ASBMT, 2006

 

 

 

 

 

Muzaffar H. Qazilbash

Professor

 

  • : 713.745.3458
    Fax: 713.794.4902
  • DEPARTMENT Department of Stem Cell Transplantation
    The University of Texas MD Anderson Cancer Center
  • COUNTRY USA